C-Jun antagonist peptides

By designing specific amino acid combinations and covalently cross-linked c-Jun antagonist peptides, the problem of developing high-affinity and selective inhibition of c-Jun DNA binding in existing technologies has been solved, achieving antagonistic effects with improved stability and permeability, and possessing therapeutic potential.

CN118984835APending Publication Date: 2024-11-19UNIVERSITY OF BATH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380033105.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-11
Filing Date
2023-03-10
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Existing technologies struggle to develop functional antagonists that exhibit high affinity and selectivity to inhibit c-Jun, especially peptides with promising pharmacokinetic properties, as they are difficult to effectively antagonize c-Jun's DNA-binding function.

Method used

A c-Jun antagonist peptide containing an amino acid sequence was designed and optimized. By combining specific amino acids in the hinge region and leucine zipper region and introducing a covalent cross-linking agent to improve the helicity and stability of the peptide, a helically constrained c-Jun antagonist was formed.

Benefits of technology

It achieves high affinity binding to c-Jun, effectively antagonizing its DNA binding function, while improving peptide stability and membrane permeability, thus possessing the potential to be used as a therapeutic agent.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005075149160000044
    Figure BDA0005075149160000044
  • Figure BDA0005075149160000051
    Figure BDA0005075149160000051
  • Figure BDA0005075149160000061
    Figure BDA0005075149160000061
Patent Text Reader

Abstract

A c-Jun antagonist is described. Also described are compositions comprising these c-Jun antagonists, as well as methods, methods of treatment comprising the c-Jun antagonists, and therapeutic uses.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to GB 2203399.7 filed on March 11, 2022, the contents and elements of which are incorporated herein by reference for all purposes. Technical Field

[0002] The present invention relates to peptides antagonizing c-Jun, nucleic acids encoding peptides antagonizing c-Jun, pharmaceutical preparations containing peptides antagonizing c-Jun, and uses of antagonist peptides in treating c-Jun-mediated diseases. Background Art

[0003] Transcription factors (TFs) play a crucial role in determining cell function and fate. A series of upstream signals converge on TFs, which convert important cell signaling processes into transcriptional outputs through specific DNA site recognition. Therefore, of the approximately 1,600 TFs in the human genome, >300 are associated with disease phenotypes. TF dysfunction leads to a range of harmful outcomes, including cancer, diabetes, and cardiovascular disease (Lee et al., 2013; Lambert et al., 2018). Therefore, selective TF antagonism is a compelling therapeutic approach for the treatment of these diseases.

[0004] c-Jun is a transcription factor involved in a series of human diseases (Eferl et al., 2003; Yung et al., 2010; Shiozawa et al., 2009). c-Jun is a member of the dimeric transcription factor activator protein-1 (AP-1) family. AP-1 protein binds to DNA recognition elements through its basic-leucine zipper (bZIP) domain, which is composed of a leucine zipper (LZ) that promotes dimerization and a DNA-binding domain (DBD) that promotes DNA sequence recognition (Glover et al., 1995; Risse et al., 1989). c-Jun binds to the 12-O-tetradecanoylphorbol-13-acetate response element (TRE) and directly affects cellular processes such as differentiation, proliferation, and survival (Shaulian et al., 2001; Eferl et al., 2003; Eckert et al., 2013; Alani et al., 1991). Therefore, dysregulation of these functions promotes hallmark cancer cell behaviors, making cJun a focus of cancer therapy.

[0005] TF function relies on protein-protein interactions (PPIs) and protein-DNA interactions that form many contact points on their large surfaces. Small molecules (SMs) are usually unable to eliminate these types of interactions due to the lack of tractable pockets.

[0006] Although planar protein-protein interactions are inaccessible to many drugs, including small molecules, peptides have excellent potential as high-affinity and selective inhibitors when they are designed to complement a wide range of target surfaces. Multiple approaches have generated peptide c-Jun antagonists that target a wide range of LZ binding interfaces (Boysen et al., 2002; Mason et al., 2006; Kaplan et al., 2014; Baxter et al., 2017; Lathbridge et al., 2018). However, it is difficult to predict whether LZ binding will translate into functional antagonism because the cJun DBD remains unbound and is able to bind TRE DNA (Seldeen et al., 2008; Szalóki et al., 2015). Rationally designed peptides have been shown to target the c-Jun DBD, but exhibit lower potency than LZ antagonists and raise concerns about specificity due to the high sequence similarity between AP-1 family DBDs (Tsuchida et al., 2004).

[0007] A method to circumvent the potential shortcomings of existing methods is to utilize longer peptides, which target complete c-Jun bZIP domains with selectivity but high-affinity interactions, blocking both DNA binding and LZ dimerization. Olive et al. adopt this method to produce A-Fos, which combines wild-type (wild-type, WT) cFos LZ (known to be heterodimerized with c-Jun) and rationally designed Glu-rich acidic extensions (Olive et al., 1997). The A-Fos design principle assumes that LZ interactions extend at the N-terminal, producing DBD-acidic extensions interactions promoted by incorporating Leu residues into the putative d position in the acidic extension.

[0008] For peptides to be able to act as functionally active c-Jun antagonists, they must not only bind to c-Jun, but target binding must also result in abrogation of function. A recently described method for identifying functional antagonists of transcription factors is the Transcription Block Survival (TBS) assay described in WO2020128015.

[0009] There remains a need for c-Jun antagonists that act as functional antagonists, particularly those that exhibit desirable pharmacokinetic properties for therapeutic use.

[0010] The present invention has been designed based on the above considerations. Summary of the invention

[0011] The present inventors have identified novel peptide inhibitors that were shown to bind c-Jun and antagonize its DNA binding function.

[0012] In work prior to the present invention, the inventors used a library-based approach in which the hinge region spanning the acidic extension and leucine zipper region of the c-Jun antagonist was semi-randomized. A peptide library was generated on this scaffold and randomized in the central tract of residues and tested using the TBS screening platform. This resulted in the identification of a recombinantly produced functional c-Jun antagonist, referred to as "HingeW," from a library of approximately 130,000 peptides. In this example, it was demonstrated that HingeW preferentially binds to c-Jun and has a higher affinity than the c-Jun antagonist from which HingeW was derived, and effectively antagonizes c-Jun / TRE DNA interactions. The properties of the wide, shallow helical binding surface of c-Jun support the use of longer peptides, such as those identified by TBS.

[0013] The binding epitope of bZIP antagonist is present on one side of a single α-helix, and therefore target binding requires peptide to adopt this secondary structure. Recognizing that the basic step of developing therapeutic peptides is to reduce the peptide to the minimum functional unit required for effective binding, the inventors have introduced iterative truncation in the antagonist peptides identified. Reduction tends to reduce the α-helicity of the peptide, because both the interaction interface and the extended internal hydrogen bond network become reduced, and water competes for these interactions, and the folding equilibrium is turned to random coil (random coil). Therefore, peptide reduction needs to be balanced with the affinity reduction caused by the reduction of the α-helicity of the peptide to improve drug-like characteristics (such as stability and membrane permeability). As shown herein, multiple optimizations and truncated forms of HingeW peptides that have retained functional activity while improving the drug-like characteristics of the peptide have been developed.

[0014] In a first aspect, the present invention provides a c-Jun antagonist comprising a compound having an amino acid sequence an extended hinge region; and a leucine zipper (LZ) region at the C-terminus of the extended hinge region,

[0015] in:

[0016] X1 is selected from V, D, K, C and R,

[0017] X2 is selected from D, K, C and R,

[0018] X3 is selected from V, D, C, K and R, and

[0019] X4 is selected from E, D, C, K and R.

[0020] In some embodiments:

[0021] X1 is selected from V, D, K and C,

[0022] X2 is selected from D, K and C,

[0023] X3 is selected from V, D and C, and

[0024] X4 is selected from E, D and C.

[0025] In some embodiments, the extended hinge region further comprises a region having an amino acid sequence The N-terminal acidic extension,

[0026] in:

[0027] X5 is selected from E, K or C, and

[0028] X6 is selected from E or D.

[0029] In some embodiments, the acidic stretch has the amino acid sequence

[0030] In some embodiments, X1 is V. In some embodiments, X3 is V. In some embodiments, X1 and X3 are V.

[0031] In some embodiments:

[0032] (i) X1 is V, X2 is D, X3 is V and X4 is E;

[0033] (ii) X1 is V, X2 is K, X3 is V and X4 is D; or

[0034] (iii) X1 is V, X2 is C, X3 is V and X4 is C.

[0035] In some embodiments, the LZ region comprises the amino acid sequence or in

[0036] [X7] is K, L, S, W, P, Q, R, M, T, V, A, E or G;

[0037] [X 8] is I, V or L;

[0038] [X9] and [X 10 ] is any amino acid residue.

[0039] [X 11 ] is Q, E or K.

[0040] In some embodiments, the LZ region comprises an amino acid sequence selected from the group consisting of:

[0041]

[0042] Or variants thereof containing 1, 2 or 3 amino acid modifications.

[0043] In some embodiments, the LZ region comprises an amino acid sequence selected from the group consisting of:

[0044]

[0045] Or variants thereof containing 1, 2 or 3 amino acid modifications.

[0046] In some embodiments, the LZ region comprises: the amino acid sequence or a variant thereof containing 1, 2 or 3 amino acid modifications,

[0047] Optionally wherein the amino acid residues at positions corresponding to position 16 (position b in the heptapeptide) and position 20 (position f in the heptapeptide) of SEQ ID NO: 7 in the variant are K and D amino acid residues, respectively.

[0048] In some embodiments, the LZ region comprises: the amino acid sequence or a variant thereof containing 1, 2 or 3 amino acid modifications,

[0049] Optionally wherein the amino acid residues at positions corresponding to position 16 (position b in the heptapeptide) and position 20 (position f in the heptapeptide) of SEQ ID NO: 27 in the variant are both C amino acid residues.

[0050] In some embodiments, the c-Jun antagonist is 30 to 70 amino acids, 30 to 60 amino acids, 30 to 50 amino acids, or 30 to 40 amino acids in length. In some specific embodiments, the c-Jun antagonist is 36 amino acids in length.

[0051] In some embodiments, the c-Jun antagonist has the following amino acid sequence:

[0052]

[0053] Or variants thereof containing 1, 2, or 3 amino acid modifications.

[0054] In some embodiments, the c-Jun antagonist comprises at least one covalent amino acid residue cross-linker. Such peptides may be referred to herein as "helical constrained c-Jun antagonists". In some embodiments, the c-Jun antagonist peptide comprises at least one covalent i to i+4 or i to i+7 amino acid residue cross-linker. As indicated herein, the introduction of a covalent amino acid residue cross-linker increases helicity and can increase the antagonist activity of the peptide. This is beneficial because it can be used to obtain such functionally active peptide antagonists: it has a binding affinity and function similar to that of the parent protein, has the same amino acid sequence that imparts specificity, while maintaining stability and solubility similar to that of a small molecule therapeutic agent. Although this has been demonstrated for K to D lactam bridges as cross-linkers, similar results are expected if other cross-linkers are used, such as alkyl cross-links (e.g., DBMB) formed between two C residues by cystine alkylation.

[0055] In some embodiments, the c-Jun antagonist peptide comprises at least one covalent i to i+4 amino acid residue cross-linker. For example, the c-Jun antagonist peptide may comprise two covalent i to i+4 amino acid cross-linkers. Preferably, the covalent i to i+4 cross-linker is present at positions b to f or f to c of the heptapeptide. Preferably, the covalent i to i+4 amino acid cross-linker is a K to D lactam bridge, or an alkyl cross-link formed between two C residues (cysteine ​​alkylation).

[0056] In a second aspect, the present invention provides a nucleic acid encoding a c-Jun antagonist peptide according to the first aspect of the invention.

[0057] In a third aspect, the present invention provides a conjugate comprising a c-Jun antagonist peptide according to the first aspect of the invention conjugated to a lipid, a polymer or a second peptide.

[0058] In a fourth aspect, the invention provides a pharmaceutical composition comprising a c-Jun antagonist according to the first aspect of the invention, a nucleic acid according to the second aspect of the invention or a conjugate according to the third aspect of the invention in combination with a physiologically acceptable excipient or carrier.

[0059] In a fifth aspect, the present invention provides a c-Jun antagonist peptide according to the first aspect of the invention, a nucleic acid according to the second aspect of the invention, a conjugate according to the third aspect of the invention or a pharmaceutical composition according to the fourth aspect of the invention for use as a medicament.

[0060] In a sixth aspect, the present invention provides a method of inhibiting c-Jun, the method comprising administering a peptide according to the first aspect of the invention, a nucleic acid according to the second aspect of the invention or a conjugate according to the third aspect of the invention to a cell comprising or expressing a c-Jun peptide in vitro.

[0061] Also provided herein are methods for producing c-Jun antagonist peptides according to the first aspect of the invention. The method for producing a c-Jun antagonist peptide may include synthesizing the c-Jun antagonist peptide using solid phase or liquid phase peptide synthesis, or may include producing the c-Jun antagonist peptide by recombinant expression. The method may also include contacting the c-Jun antagonist peptide with a cross-linking agent to produce a helical constrained c-Jun antagonist peptide. Additionally provided herein are methods for producing a helical constrained c-Jun antagonist peptide, comprising contacting the c-Jun antagonist peptide according to the first aspect of the invention with a cross-linking agent.

[0062] The present invention includes combinations of the described aspects and preferred features except where such combinations are expressly impermissible or explicitly avoided.

[0063] These and other aspects of the invention are described in more detail below. BRIEF DESCRIPTION OF THE DRAWINGS

[0064] Some embodiments and experiments illustrating the principles of the present invention will now be discussed with reference to the accompanying drawings, in which:

[0065] Figure 1 - TRE DNA-bound cJun structure and cJun antagonist design. (A) The crystal structure of the DNA-bound cJun homodimer (PDB: 2H7H) is shown to highlight the LZ and DBD components required for dimerization and DNA binding. (B) A schematic diagram of the acidic extension design principle (A-FosW, HingeW) is shown. This takes advantage of the region known to bind to the cJun LZ, to which a Glu-rich extension is appended to interact with the cJun DBD.

[0066] Figure 2 -Shows the protein and DNA sequence of TRE-mDHFR with 15 TRE sites introduced into the gene. The amino acids and DNA bases mutated from the WT mouse protein are shown in red, and the TRE DNA sites to which these mutations have been added are bolded and underlined. Green shows the NheI and HindIII sites used to subclone the gene into the pES300d vector.

[0067] Fig. 3-mDHFR retains activity after introducing TRE site.(A) Fifteen TRE sites are introduced into mDHFR gene (two silences and thirteen replacements) to allow transcriptional blocking induced by cJun.Replacement mapping (green) is on mDHFR structure (PDB code: 1U72), indicating surface exposure at distal position of active site, where substrate DHF (competitive inhibitor methotrexate (methotrexate, MTX) combined in DHF binding site) and cofactor NADPH are combined.Measure the change of absorbance at 340nm to determine the NADPH turnover rate of (B) WT-mDHFR and (C) TRE-mDHFR with or without substrate DHF.Also shown is the reaction repeated in the presence of TMP, indicating that both enzymes retain activity, wherein as expected, TRE-mDHFR partially inhibits. Specific activity is calculated by linear initial rate (first 2.5 minutes for WT-mDHFR, first 10 minutes for TRE-mDHFR; minus the reaction blank of only +NADPH). Data are mean values ​​from triplicate experiments, with error expressed as one standard deviation. MTX exhibits a wider range of inhibition than TMP, inhibiting both eukaryotic and prokaryotic DHFR enzymes, and therefore inhibiting both WT-mDHFR and TRE-mDHFR.

[0068] Figure 4-TRE-mDHFR is expressed in the soluble fraction and can be purified for further study. (A) SDS-PAGE analysis of E. coli cell lysates from cells before and after induction of TRE-mDHFR plasmid expression with IPTG (1mM, 18 hours, 30°C). The total (total, T) sample was taken directly after lysis, and the soluble (soluble, S) sample was taken after the lysate was centrifuged. This shows that protein bands appear in the induced samples, and the band intensities in the T and S fractions are equal, indicating that the protein is folded and soluble. TRE-mDHFR can bind to an immobilized metal affinity chromatography column due to its 6xHis-tag, and then eluted by an imidazole gradient (B) to obtain pure protein, as determined by (C) SDS-PAGE of the combined and concentrated fractions, showing that it contains induced protein bands. TRE-mDHFR did not migrate through the polyacrylamide gel as predicted by the protein marker lane (M), running at a significantly higher molecular weight, but its identity was confirmed by (D) electrospray ionization mass spectrometry.

[0069] Figure 5- Optimization of the TMP concentration required to produce selectivity between E. coli expressing TRE-mDHFR and E. coli in which TRE-mDHFR expression was transcriptionally blocked by cJun-bZIP. A controlled number of E. coli cells expressing the indicated protein were plated on selective media at different TMP concentrations. 4 μM TMP produced the best difference in colony numbers between TRE-mDHFR only and TRE-mDHFR+cJun bZIP plates.

[0070] Figure 6 - Bacterial DHFR can be inhibited by TMP and its activity is replaced by the induction of TRE-mDHFR expression. According to the design principles of the TBS assay, E. coli cells containing a plasmid targeting only TRE-mDHFR grow differentially on different agar media. In M9 agar (1), a bacterial lawn is produced as the bacteria grow freely; after adding TMP to the medium (2), bacterial DHFR is inhibited and the cells cannot grow; and further addition of IPTG (3) leads to the expression of TRE-mDHFR, which restores cell survival to a certain extent.

[0071] Figure 7 -WT-mDHFR and TRE-mDHFR are both inhibited by the broad DHFR inhibitor MTX. The change in absorbance at 340nm was measured to determine the NADPH turnover of WT-mDHFR and TRE-mDHFR with and without the substrate DHF. The reaction repeated in the presence of MTX is also shown, which shows a clear inhibition of the reaction (as expected) and indicates DHFR activity.

[0072] Figure 8 - Transcription blocking survival (TBS) assay to obtain functionally active cJun inhibitors. (A) Schematic diagram showing the design and operation of TBS. (B) Controlled numbers of E. coli expressing the indicated proteins were inoculated on selective media and growth rates were calculated by counting colony forming units. (1) WT-mDHFR expression substituted for ecDHFR and was not inhibited by TMP resulting in significant growth. (2) When cJun bZIP was additionally expressed, a small effect on colony number was observed. (3) TRE-mDHFR substituted for the inhibited ecDHFR, with colony counts lower than those of WT, as expected. (4) The cJunLZ domain (lacking DBD) did not affect TRE-mDHFR transcription and colony formation, however, (5) the cJun bZIP domain (with DBD) bound to the TRE site to block transcription of TRE-mDHFR, resulting in reduced bacterial survival. Although (6) cFos LZ and (7) FosW are known cJun binders, they were not able to effectively dissociate cJun bZIP from TRE DNA. However, (8) A-FosW and TBS-derived hit (9) HingeW removed the TRE-mDHFR transcription block to restore cell survival. The bar graph represents the mean of three experimental replicates. Errors are expressed as one standard deviation. The P values ​​selected from the t-test (*P≤0.05; **P≤0.01; ****P≤0.0001) and all possible comparisons are indicated in the bar graph reported in Figure S7. Serial dilutions were used to quantify colony counts when necessary. Representative plate images and schematics illustrating the effects on TRE-mDHFR transcription are also shown.

[0073] Fig. 9 -Target and antagonist peptide sequences and TBS library design. The cJun target sequence is shown and compared with the related off-target cFos. In order to promote the optimization of cJun binding, nine residues in the ten residue segments (e4 to g5) in the A-FosW sequence are selected for variation in the library, providing acidic, polar and hydrophobic options, and a library of 131,072 members is generated. Screening using TBS has produced a "HingeW" sequence. The DBD and acidic extension regions are shown in blue or red, respectively, and the library options selected in the winning peptides are highlighted in green. Residues are named according to the heptapeptide numbering and the position in the given heptapeptide repeat.

[0074] Fig.10-TBS selection pressure shifts the representation of library members in DNA pool sequencing toward the selection of HingeW as the assay winner. Sequence logo showing the relative abundance of amino acids on the initial selection plate (nine colonies sequenced), the first passage (six colonies sequenced), and the final winner (HingeW; the only sequence present in the DNA pool and five colonies).

[0075] Figure 11 - TBS winning peptide HingeW preferentially binds cJun relative to A-FosW. CD spectra (20°C) show binding of cJun to (A) HingeW or (B) A-FosW. In both cases, the heterodimer spectra show an increased α-helical character relative to the average of the component peptides. However, the effect is greater for HingeW, indicating a greater increase in peptide helicity. Similarly, the thermal denaturation of cJun bound to (C) HingeW or (D) A-FosW is right-shifted from the average of the component peptide denaturation spectra. Due to the T of the HingeW homodimer, the m HingeW / cJun showed a larger binding ΔT than A-FosW / cJun m (Indicated by arrows). CD dimer exchange spectra show that (E) when HingeW is mixed with A-FosW / cJun heterodimers, the helicity increases because HingeW exchanges with A-FosW due to the binding preference of cJun for HingeW, and (F) when A-FosW is mixed with HingeW / cJun heterodimers, no shift relative to the mean is observed, indicating that the dimer population does not change. Arrows are shown to highlight the shift relative to the mean at 190 and 222 nm. In all experiments, the total sample peptide concentration was fixed to 10 μM using equimolar concentrations of each component peptide to remove concentration-dependent effects.

[0076] Fig.12 - shows the CD thermal denaturation spectrum of the interaction between FosW and cJun bZIP. The thermal denaturation curve of the FosW / cJun bZIP heterodimer deviates from the average of the curves of the two component peptides. This indicates that the helicity and T m The value (54°C for the heterodimer) was increased, indicating a binding interaction.

[0077] Fig.13 -TBS winning peptide HingeW does not interact with cFos. CD spectra and thermal denaturation curves indicate that there is no interaction between HingeW and cFos, as the measured heterodimer spectra / thermal denaturation curves overlap with the average of the individual component spectra.

[0078] Figure 14 - Isothermal titration calorimetry data show that HingeW / cJun has a 6-fold higher affinity than A-FosW / cJun. ITC analysis of cJun binding to (A) HingeW and (B) A-FosW shows the original power compensation plot throughout the titration in the upper panel and the integrated data points and single-site model fit (MicroCal ORIGIN software) in the lower panel.

[0079] Figure 15 - HingeW antagonizes cJun / TRE DNA interactions more effectively than A-FosW. (A) CD spectra show that after adding cJun, the TRE DNA peak shifts at about 281 nm, which is reversed by titrating HingeW into the sample because HingeW sequesters cJun in a non-functional heterodimer. (B) Relative peak shifts from bound TRE to free TRE are plotted for different concentrations of HingeW and A-FosW, showing greater cJun / TRE DNA inhibition by HingeW at all concentrations. EMSA shows (C) displacement of unbound TRE DNA bands after adding cJun and subsequent recovery of unbound DNA band intensity after titrating (D) HingeW or (E) A-FosW. (F) For both CD and EMSA, data are averages from three independent experiments, and the plotted error bars represent one standard deviation.

[0080] Fig.16 - CD antagonism data showing the shift in the DNA spectrum after the addition of FosW to cJun-bound DNA. The relative shift from the cJun-bound TRE DNA peak to the free TRE DNA peak was monitored at 281 nm with the sequential addition of FosW. Data are the average of three independent experiments.

[0081] Fig.17 -HingeW and A-FosW do not interact with TRE DNA. CD spectra show no interaction between HingeW or A-FosW and TRE DNA. Proteins do not absorb in this wavelength range, so the observed CD signal is due to the DNA structure, which is not disturbed after the addition of either protein.

[0082] Figure 18 - Iterative N-terminal truncations of HingeW reduce c-Jun binding and antagonism. (A) Thermal denaturation profiles of iteratively truncated peptide (5 μM) / c-Jun (5 μM) heterodimer samples. (B) CD antagonism data generated by monitoring the shift of the DNA-specific peak to provide a direct readout of cJun-induced DNA binding.

[0083] Fig.19 -T m Value and IC 50 With the formation of peptide-cJun heterodimer (i.e. binary complex), T m A direct correlation with improved cJun / TRE DNA antagonism (antagonism of DNA binding, in which ternary complex formation is blocked) was observed, as evidenced by lower IC 50 Value shown.

[0084] Fig. 20 - ITC data showing thermodynamic parameters of c-Jun peptide interactions

[0085] Fig.21 - Lactamization leads to enhanced serum stability. The amount of peptide detected by LC-MS was plotted compared to the starting point and showed that the linear peptides degraded faster than the lactamized peptides, with the dilactamylated 24 showing the highest stability.

[0086] Figure 22 - Quantification of peptide optimization by CD to determine peptide helicity, c-Jun target binding, and c-Jun / TRE DNA antagonism. Biophysical characteristics of selected peptides are shown to illustrate the effects and exemplary data observed throughout the optimization process. (A) Spectra of selected peptides (10 μM), which show increased helicity from truncation at the N-terminus, decreased helicity from truncation at the C-terminus, and increased helicity due to lactamization. (B) Thermal denaturation spectra of selected antagonist (5 μM) / cJun (5 μM) heterodimer samples. (C) CD spectra show the shift of the TRE DNA peak at about 281 nm after adding cJun, which is reversed by titrating HingeW into the sample because HingeW sequesters cJun in non-functional heterodimers. (D) Relative peak shifts from bound TRE to free TRE are plotted for different peptide concentrations.

[0087] Fig.23 - Optimization of bis-alkylated HingeW peptide variants. CD antagonism data were generated by monitoring the transition from bound to free TRE to provide a direct readout of cJun-induced DNA binding of the tested cyclized HingeW (mDBMBW cyclized and OW cyclized) versus linear HingeW (mDBMBW linear and OW linear) variants. DETAILED DESCRIPTION

[0088] Some aspects and embodiments of the present invention will now be discussed with reference to the accompanying drawings. Other aspects and embodiments will be apparent to those skilled in the art. All documents mentioned herein are incorporated herein by reference.

[0089] The c-Jun antagonists described herein generally comprise a hinge region of V[X1]EE[X2][X3]LE[X4]E, more preferably having the amino acid sequence and a leucine zipper (LZ) region at the C-terminus of the extended hinge region, wherein X1 is V, D, K, C or R, X2 is K, D, C or R, X3 is V, D, C, K or R, and X4 is selected from E, D, C, K or R. c-Jun antagonists are also referred to herein as "c-Jun antagonist peptides."

[0090] Extended hinge area

[0091] In this specification, the term "hinge region" is intended to mean an amino acid segment of ten residues. The amino acid residues in this segment can be acidic residues (D / E) and hydrophobic residues (V), and optionally, K residues can be present. The "hinge region" of c-Jun antagonists is so named because it corresponds to the "hinge" forming part of both the DBD domain and the LZ domain of c-Jun, and is therefore able to interact with these two domains in c-Jun. The presence of the hinge region provides a peptide with the ability to bind to c-Jun and antagonize its DNA binding activity. The main negative charge in the hinge region is also believed to lead to a favorable interaction with the positive charge in the c-Jun DNA binding domain (DBD).

[0092] The extended hinge region comprises the hinge region and L residues at its N-terminal portion. The extended hinge region may have the amino acid sequence Wherein X1 is selected from V, D, K, C and R, X2 is selected from D, K, C and R, X3 is selected from V, D, C, K and R, and X4 is selected from E, D, C, K and R. In some embodiments, X1 is selected from V, D, K and C, X2 is selected from K, D and C, X3 is selected from V, D or C, and X4 is selected from E, D, C or R. Additional negatively charged amino acid residues are believed to facilitate interaction with the positively charged DBD of c-Jun. Variants of the extended hinge region sequences described herein are also contemplated, wherein the variants contain 1, 2 or 3 amino acid modifications.

[0093] In some embodiments, X1 is V, and / or X3 is V. In some embodiments, X2 is D and X4 is E. For example, the extended hinge region may comprise the amino acid sequence

[0094] In other embodiments, X2 is K and X4 is D. For example, the extended hinge region may comprise the amino acid sequence Such an amino acid sequence can be used, for example, to introduce an i to i+4 K to D lactam bridge in the b to f heptad positions of the hinge region of an antagonist.

[0095] In other embodiments, X1 is K and X3 is D. For example, the extended hinge region may comprise the amino acid sequence Such an amino acid sequence can be used, for example, to introduce an i to i+4 K to D lactam bridge in the f to c heptad positions of the hinge region of an antagonist.

[0096] In other embodiments, X2 is C and X4 is C. For example, the extended hinge region may comprise the amino acid sequence Such an amino acid sequence can be used, for example, to introduce i to i+4 alkyl cross-links in the b to f heptad positions of the hinge region of the antagonist.

[0097] In other embodiments, X1 is C and X3 is C. For example, the extended hinge region may comprise the amino acid sequence Such an amino acid sequence can be used, for example, to introduce i to i+4 alkyl cross-links in the f to c heptad positions of the hinge region of the antagonist.

[0098] In other embodiments, X1 is C and X4 is C. For example, the extended hinge region may comprise the amino acid sequence Such an amino acid sequence can be used, for example, to introduce i to i+7 alkyl cross-links in the f to f heptad positions of the hinge region of an antagonist.

[0099] In some embodiments, one or more of X1, X2, X3, and X4 is R or K. In one embodiment, X 4 is R or K. For example, the extended hinge region may comprise the amino acid sequence As described below, the introduction of arginine or lysine at solvent-exposed positions can increase the cell permeability of the peptide.

[0100] Acidic extension

[0101] According to the present invention, the extended hinge region may also include a region having an amino acid sequence The N-terminal acidic extension of wherein X5 is selected from E, K and C, and X6 is selected from E, D and C. In some embodiments, X6 is selected from E and D (eg, X6 is E).

[0102] The N-terminal acidic extension is believed to produce electrostatic repulsion, favorably reducing the tendency of the peptide to homodimerize, thereby making more peptide antagonists available for heterodimerization with c-Jun. The negative charge of the entire N-terminal domain of the acidic extension favorably interacts with the positive charge of the c-Jun DBD.

[0103] In some embodiments, X1 (in the extended hinge region) is D, and X5 (in the acidic extension) is K. Such an amino acid sequence can be used, for example, to introduce an i to i+4 K to D lactam bridge spanning the acidic extension (heptapeptide position b) and hinge region (heptapeptide position f) of the antagonist.

[0104] In some embodiments, X1 (in the extended hinge region) is C, and X5 (in the acidic extension) is C. Such an amino acid sequence can be used, for example, to introduce an i to i+4 alkyl cross-link across the acidic extension (heptad position b) and hinge region (heptad position f) of the antagonist.

[0105] According to the present invention, the acidic extension may have the amino acid sequence EAEE (SEQ ID NO: 3). This amino acid sequence is believed to induce helicity and stabilize the dipole of the molecule. Another advantage of the EAEE sequence is that its two central residues AE appear at positions corresponding to interactions with DNA on c-Jun, thereby forming a direct block between c-Jun and DNA.

[0106] LZ Zone

[0107] The LZ region of the antagonist of the present invention is located at the C-terminus of the hinge region and is capable of interacting with the leucine zipper of c-Jun.

[0108] According to the present invention, the LZ region may comprise or consist of an amino acid sequence selected from the following:

[0109]

[0110] Or a variant thereof. The variant may comprise one or more amino acid modifications. For example, the variant may comprise 1, 2, 3, 4 or 5 amino acid modifications. For example, the variant comprises 1, 2 or 3 amino acid modifications.

[0111] In some embodiments, the LZ region comprises or consists of the amino acid sequence Or a variant comprising 1, 2 or 3 modifications. In some embodiments, the amino acid residues at positions corresponding to 16 (b in the heptapeptide) and 20 (f in the same heptapeptide) of SEQ ID NO: 7 in the variant are K and D amino acid residues, respectively (i.e., the amino acid modifications are at positions other than positions 16 and 20 corresponding to SEQ ID NO: 7).

[0112] In some embodiments, the LZ region comprises or consists of the amino acid sequence Or a variant comprising 1, 2 or 3 modifications. In some embodiments, the amino acid residues at positions corresponding to 16 (position b in the heptapeptide) and 20 (position f in the same heptapeptide) of SEQ ID NO: 27 in the variant are both C amino acid residues (i.e., the amino acid modifications are at positions other than positions 16 and 20 corresponding to SEQ ID NO: 27).

[0113] In some embodiments, the LZ region comprises:

[0114]

[0115] Where [X7] is K, L, S, W, P, Q, R, M, T, V, A, E or G;

[0116] [X8] is I, V or L;

[0117] [X9] and [X 10 ] is any amino acid residue;

[0118] [X 11 ] is Q, E or K.

[0119] In some embodiments, the LZ region comprises:

[0120]

[0121] Such an LZ region is suitable for bis-alkylation, as described in more detail below.

[0122] In some embodiments, the LZ region comprises one or more lysine and / or arginine at positions b, c and / or f of the heptapeptide in the LZ region. In some embodiments, the lysine or arginine is located at a position other than the position for introducing crosslinks (e.g., lactam bridges or dialkylation). As described in more detail below, the introduction of positively charged amino acids at the solvent-exposed face of the alpha-helical peptide can improve cell permeability.

[0123] Thus, in some embodiments, the LZ region comprises or consists of the amino acid sequence Or a variant comprising 1, 2 or 3 modifications. In some embodiments, the amino acid residues at the positions corresponding to position 16 (position b in the heptapeptide) and position 20 (position f in the same heptapeptide) of SEQ ID NO: 74 in the variant are K and D amino acid residues, respectively (i.e., the amino acid modification is located at positions other than positions 16 and 20 corresponding to SEQ ID NO: 74). In some embodiments, the amino acid residues at the positions corresponding to position 2 (position b in the heptapeptide) and position 3 (position c in the heptapeptide) and position 9 (position b in the heptapeptide) of SEQ ID NO: 74 in the variant are K or R (optionally R) (i.e., the amino acid modification is located at positions other than positions 2, 3 and 9 corresponding to SEQ ID NO: 74). In some embodiments, the amino acid modification is located at positions other than positions 2, 3, 9, 16 and 20 corresponding to SEQ ID NO: 74.

[0124] In other embodiments, the LZ region comprises or consists of the amino acid sequence Or a variant comprising 1, 2 or 3 modifications. In some embodiments, the amino acid residues at the positions corresponding to position 16 (position b in the heptapeptide) and position 20 (position f in the same heptapeptide) of SEQ ID NO: 75 in the variant are K and D amino acid residues, respectively (i.e., the amino acid modification is located at positions other than 16 and 20 corresponding to SEQ ID NO: 75). In some embodiments, the amino acid residues at the positions corresponding to position 3 (position c in the heptapeptide), position 10 (position c in the heptapeptide) and position 13 (position f in the heptapeptide) of SEQ ID NO: 75 in the variant are K or R (optionally R) (i.e., the amino acid modification is located at positions other than positions 3, 10 and 13 corresponding to SEQ ID NO: 75). In some embodiments, the amino acid modification is located at positions other than positions 3, 10, 13, 16 and 20 corresponding to SEQ ID NO: 75.

[0125] Antagonists and properties

[0126] As described herein, c-Jun antagonists are peptides and can be in D- or L-form. "Peptide" as used herein includes compounds consisting of or comprising a linear chain of amino acids connected by peptide bonds, and can be any peptide, polypeptide or protein. The amino acid residues forming the peptide antagonists can be made up of D- or L-type amino acid residues or a mixture of the two. In this manual, peptide compounds are generally referred to as peptides.

[0127] A c-Jun antagonist as described herein may be isolated in the sense of being free of contaminants (eg, other polypeptides and / or cellular components).

[0128] The c-Jun antagonists as described herein may be in free form or in the form of any pharmaceutically acceptable salt, such as an acid salt, a metal salt, an alkaline earth metal salt or an amine salt.

[0129] The c-Jun antagonist can be 10 to 100 amino acid residues long. The c-Jun antagonist can be less than 70, preferably less than 60, more preferably less than 55, even more preferably less than 50, still more preferably less than 45, and still more preferably less than 40 amino acids long. The c-Jun antagonist can be 30 to 70, 30 to 60, 30 to 50, or 30 to 40 amino acid residues long. For example, the length of the c-Jun antagonist can be 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57 amino acids in length. In certain embodiments, the length of the c-Jun antagonist is 36 amino acids.

[0130] The c-Jun antagonist may be a HingeW peptide or a variant thereof. The HingeW peptide comprises the amino acid sequence HingeW peptides may also contain one or more of the following: MAS at the N-terminus, GAP at the C-terminus, and a 6xHis tag at the C-terminus As described herein, the HingeW peptide was demonstrated to bind to the target c-Jun protein with high affinity and antagonize the DNA binding function of c-Jun, and was therefore demonstrated to be a functional antagonist of c-Jun.

[0131] The c-Jun antagonist can be a truncated form of a HingeW peptide or a variant thereof. As described herein, a variety of truncated HingeW peptides have been developed and shown to be functional antagonists of HingeW. Although the functional antagonism of these truncated forms is reduced compared to the HingeW peptide, the truncated peptides are considered to exhibit more drug-like characteristics compared to the full-length HingeW peptide, indicating that these truncated forms also represent effective therapeutic candidates for antagonizing c-Jun function.

[0132] As used herein, a "functional antagonist" of c-Jun is a peptide compound that can bind to c-Jun and inhibit its DNA binding activity. The method for identifying functional antagonist peptides includes the transcription blocking survival (TBS) assay described in Example 1. In short, in TBS, the coding region of the essential gene dihydrofolate reductase (DHFR) is mutated to incorporate into the TRE site so that c-Jun is introduced into the gene in Escherichia coli, resulting in a transcription blockade that eliminates cell proliferation. The c-Jun molecules bound by the TRE site spatially prevent RNA polymerase from transcribing essential genes, and this can only be restored after the introduction of an effective c-Jun / TRE antagonist. Therefore, the survival of specific cells is controlled by the ability of peptide library members to remove c-Jun transcription blocking and thus restore DHFR activity. Therefore, TBS helps to identify sequences with therapeutic value. Additional details of TBS assays are provided in WO2020128015, which is incorporated herein by reference in its entirety.

[0133] Other methods for determining antagonism of c-Jun include circular dichroism (CD) assays, as described in Example 2. Briefly, the assay involves preparing a peptide and a TRE-DNA construct. The sample was titrated and the signal was measured between 265 and 320 nm. The TRE-DNA construct produces a positive CD peak at about 281 nm, which decreases in intensity after c-Jun binding. If the peptide is able to antagonize c-Jun DNA binding activity, increasing the concentration of the peptide will shift the peak back to the free TRE-DNA peak. Therefore, the peak shift can be used to quantify the ability of the peptide to antagonize c-Jun DNA binding. This method allows the calculation of the IC by fitting the titration data to the Hill equation. 50 value.

[0134] In some embodiments, the c-Jun antagonist is capable of inhibiting the DNA binding activity of c-Jun within 10 times the ability of HingeW to inhibit the DNA binding activity of c-Jun (e.g., the ability of the c-Jun antagonist to inhibit the DNA binding activity of c-Jun is reduced, which is within 10 times the ability determined for HingeW). In some embodiments, the c-Jun antagonist is capable of inhibiting the DNA binding activity of c-Jun within 9 times, preferably within 8 times, more preferably within 7 times, even more preferably within 6 times, and even more preferably within 5 times the ability of HingeW to inhibit the DNA binding activity of c-Jun. The ability of the c-Jun antagonist and HingeW to inhibit DNA binding activity can be determined using a TBS assay (e.g., by quantifying the number of colonies) or by using a circular dichroism assay as described herein to determine the IC50 Optionally, the c-Jun antagonist may have this activity when cross-linked. Methods for cross-linking peptides are described in more detail below.

[0135] In some embodiments, the c-Jun antagonist comprises or consists of any one of the following amino acid sequences:

[0136]

[0137] Or a variant thereof containing 1, 2 or 3 amino acid modifications, optionally wherein said 1, 2 or 3 amino acid modifications are present in the LZ region.

[0138] As described herein, the c-Jun antagonist amino acid sequence can be modified so that a covalent i to i+4 cross-linker or i to i+7 cross-linker is introduced into the c-Jun antagonist. The covalent i to i+4 amino acid cross-linker can be a K to D lactam bridge, or can be an alkyl cross-link (cysteine ​​alkylation) formed between two C residues. Preferably, i to i+4 amino acid residues are cross-linked to prevent the binding surface of the helix from being destroyed at the solvent-exposed b to f (in a heptad) or f to c (across two heptads) heptad positions. In this specification, the heptad numbering refers to the positioning of a specific amino acid residue within a heptad repeat, which is a structural motif consisting of a repeating pattern of seven amino acids. The position of the heptad repeat is usually represented by lowercase a to g (usually abcdefg). Table 5 below shows how the heptad number corresponds to the HingeW amino acid sequence.

[0139] Thus, provided herein is a c-Jun antagonist comprising the amino acid sequence A modified form of wherein the modification comprises one or more (e.g., one or two) of the following:

[0140] (i) the amino acid residues at positions corresponding to position 3 (position b in the heptapeptide) and position 7 (position f in the same heptapeptide) of SEQ ID NO: 18 are K and D amino acid residues, respectively, or both are C amino acid residues;

[0141] (ii) the amino acid residues at positions corresponding to position 10 (position b in the heptapeptide) and position 14 (position f in the same heptapeptide) of SEQ ID NO: 18 are K and D amino acid residues, respectively, or both are C amino acid residues;

[0142] (iii) the amino acid residues at positions corresponding to position 17 (position b in the heptapeptide) and position 21 (position f in the same heptapeptide) of SEQ ID NO: 18 are K and D amino acid residues, respectively, or both are C amino acid residues;

[0143] (iv) the amino acid residues at positions corresponding to position 24 (position b in the heptapeptide) and position 28 (position f in the same heptapeptide) of SEQ ID NO: 18 are K and D amino acid residues, respectively, or both are C amino acid residues; and

[0144] (v) the amino acid residues at positions corresponding to position 31 (position b in the heptapeptide) and position 35 (position f in the same heptapeptide) of SEQ ID NO: 18 are K and D amino acid residues, respectively, or both are C amino acid residues,

[0145] Alternatively, it comprises 1, 2, 3 or 4 amino acid modifications outside of said positions (ie, outside of positions b and f in each heptad).

[0146] Also provided herein is a c-Jun antagonist comprising the amino acid sequence A modified form of wherein the modification comprises one or more (e.g., one or two) of the following:

[0147] (i) the amino acid residues at positions corresponding to position 7 (the fth position in the heptapeptide) and position 11 (the cth position in the subsequent heptapeptide) of SEQ ID NO: 18 are K and D amino acid residues, respectively, or both are C amino acid residues;

[0148] (ii) the amino acid residues at positions corresponding to position 14 (position f in the heptapeptide) and position 18 (position c in the subsequent heptapeptide) of SEQ ID NO: 18 are K and D amino acid residues, respectively, or both are C amino acid residues;

[0149] (iii) the amino acid residues at positions corresponding to position 21 (position f in the heptapeptide) and position 25 (position c in the subsequent heptapeptide) of SEQ ID NO: 18 are K and D amino acid residues, respectively, or both are C amino acid residues; and

[0150] (iv) the amino acid residues at positions corresponding to position 28 (position f in the heptapeptide) and position 32 (position c in the subsequent heptapeptide) of SEQ ID NO: 18 are K and D amino acid residues, respectively, or both are C amino acid residues,

[0151] Alternatively, it comprises 1, 2, 3 or 4 amino acid modifications outside of said positions (ie, outside of position f in one heptad and position c in the subsequent heptad).

[0152] Also provided are c-Jun antagonists wherein the amino acid sequence has been modified so that an i to i+7 cross-linker is introduced into the c-Jun antagonist. The covalent i to i+7 amino acid cross-linker can be an alkyl cross-linker formed between two C residues (cysteine ​​alkylation). Preferably, the i to i+7 amino acid residue cross-links are introduced at solvent exposed b to b, c to c or f to f (spanning two heptads) heptad positions.

[0153] Thus, provided herein is a c-Jun antagonist comprising the amino acid sequence A modified form of wherein the modification comprises one or more (e.g., one or two) of the following:

[0154] (i) the amino acid residues at positions corresponding to position 3 (the b-th position in the heptapeptide) and position 10 (the b-th position in the subsequent heptapeptide) of SEQ ID NO: 18 are both C amino acid residues;

[0155] (ii) the amino acid residues at positions corresponding to position 10 (the b-th position in the heptapeptide) and position 17 (the b-th position in the subsequent heptapeptide) of SEQ ID NO: 18 are both C amino acid residues;

[0156] (iii) the amino acid residues at positions corresponding to position 17 (the b-th position in the heptapeptide) and position 24 (the b-th position in the subsequent heptapeptide) of SEQ ID NO: 7 are both C amino acid residues;

[0157] (iv) the amino acid residues at positions corresponding to position 24 (the b-th position in the heptapeptide) and position 31 (the b-th position in the subsequent heptapeptide) of SEQ ID NO:7 are both C amino acid residues;

[0158] (v) the amino acid residues at positions corresponding to position 4 (the c-th position in the heptapeptide) and position 11 (the c-th position in the subsequent heptapeptide) of SEQ ID NO: 18 are both C amino acid residues;

[0159] (vi) the amino acid residues at positions corresponding to position 11 (the c-th position in the heptapeptide) and position 18 (the c-th position in the subsequent heptapeptide) of SEQ ID NO: 18 are both C amino acid residues;

[0160] (vii) the amino acid residues at positions corresponding to position 18 (the c-th position in the heptapeptide) and position 25 (the c-th position in the subsequent heptapeptide) of SEQ ID NO: 18 are both C amino acid residues;

[0161] (viii) the amino acid residues at positions corresponding to position 25 (the c-th position in the heptapeptide) and position 32 (the c-th position in the subsequent heptapeptide) of SEQ ID NO: 18 are both C amino acid residues;

[0162] (ix) the amino acid residues at positions corresponding to position 7 (the fth position in the heptapeptide) and position 14 (the fth position in the subsequent heptapeptide) of SEQ ID NO: 18 are both C amino acid residues;

[0163] (x) the amino acid residues at positions corresponding to position 14 (the fth position in the heptapeptide) and position 21 (the fth position in the subsequent heptapeptide) of SEQ ID NO: 18 are both C amino acid residues;

[0164] (xi) the amino acid residues at positions corresponding to position 21 (the fth position in the heptapeptide) and position 28 (the fth position in the subsequent heptapeptide) of SEQ ID NO: 18 are both C amino acid residues; and

[0165] (xii) the amino acid residues at positions corresponding to position 28 (the fth position in the heptapeptide) and position 35 (the fth position in the subsequent heptapeptide) of SEQ ID NO: 18 are both C amino acid residues,

[0166] Alternatively, it comprises 1, 2, 3 or 4 amino acid modifications outside of said positions (ie outside of position b, c or f, respectively).

[0167] In some preferred embodiments, the c-Jun antagonist comprises or consists of the following amino acid sequence:

[0168]

[0169] Or a variant thereof containing 1, 2 or 3 amino acid modifications, optionally wherein said 1, 2 or 3 amino acid modifications are present in the LZ region.

[0170] In some more preferred embodiments, the c-Jun antagonist comprises or consists of the following amino acid sequence:

[0171]

[0172] Or a variant thereof containing 1, 2 or 3 amino acid modifications, optionally wherein said 1, 2 or 3 amino acid modifications are present in the LZ region.

[0173] For example, in some embodiments where the c-Jun antagonist comprises a K to D lactam bridge, the c-Jun antagonist may comprise or consist of the following amino acid sequence:

[0174]

[0175] Or a variant thereof containing 1, 2 or 3 amino acid modifications, optionally wherein the 1, 2 or 3 amino acid modifications are present in the LZ region, and optionally wherein the amino acid residues at positions corresponding to 31 (b-th position in the heptapeptide) and 35 (f-th position in the heptapeptide) of SEQ ID NO: 10 in the variant are K and D amino acid residues, respectively.

[0176] As another example, in some embodiments where the c-Jun antagonist comprises two K to D lactam bridges, the c-Jun antagonist can comprise or consist of the following amino acid sequence:

[0177] Or a variant thereof containing 1, 2 or 3 amino acid modifications, optionally wherein the 1, 2 or 3 amino acid modifications are present in the LZ region, and optionally further wherein the amino acid residues at positions corresponding to position 10 (position b in the first heptapeptide) and position 14 (position f in the first heptapeptide) of SEQ ID NO: 11 in the variant are K and D amino acid residues, respectively, and wherein the amino acid residues at positions corresponding to position 31 (position b in the second heptapeptide) and position 35 (position f in the second heptapeptide) of SEQ ID NO: 11 in the variant are K and D amino acid residues, respectively.

[0178] As another example, in some embodiments where the c-Jun antagonist comprises an alkyl cross-link, the c-Jun antagonist can comprise or consist of the following amino acid sequence:

[0179]

[0180] Or a variant thereof containing 1, 2 or 3 amino acid modifications, optionally wherein the 1, 2 or 3 amino acid modifications are present in the LZ region, and optionally wherein the amino acid residues at positions corresponding to 31 (b-th position in the heptapeptide) and 35 (f-th position in the same heptapeptide) of SEQ ID NO: 28 in the variant are both C amino acid residues.

[0181] As another example, in some embodiments where the c-Jun antagonist comprises an alkyl cross-link, the c-Jun antagonist can comprise or consist of the following amino acid sequence:

[0182]

[0183] Or a variant thereof containing 1, 2 or 3 amino acid modifications, optionally wherein the amino acid modifications are present in the LZ region.

[0184] Amino acid modification can be insertion, replacement or deletion. In some embodiments, amino acid modification is the replacement of an amino acid residue to any other amino acid residue. The replaced amino acid residue can be a D- or L-form, and can be a naturally occurring amino acid residue or a non-naturally occurring amino acid residue.

[0185] Naturally occurring residues can be divided into the following categories based on common side-chain properties:

[0186] 1) Non-polar, aliphatic (hydrophobic): glycine (G), methionine (M), alanine (A), valine (V), leucine (L), isoleucine (I);

[0187] 2) Polar, uncharged: cysteine ​​(C), serine (S), threonine (T), asparagine (N), glutamine (Q), proline (P);

[0188] 3) Acidic (negatively charged): aspartic acid (D), glutamic acid (E);

[0189] 4) Basic (positively charged): histidine (H), lysine (K), arginine I;

[0190] 5) Aromatic: tryptophan (W), tyrosine (Y), phenylalanine (F).

[0191] Amino acid substitutions can be conservative amino acid substitutions. Conservative amino acid substitutions can involve the exchange of a member of one of these classes with another member of the same class. For example, a conservative amino acid substitution can be the replacement of the acidic amino acid glutamic acid (E) with the acidic amino acid aspartic acid (D).

[0192] Amino acid substitutions (e.g., conservative amino acid substitutions) can encompass non-naturally occurring amino acid residues, which are typically incorporated by chemical peptide synthesis rather than by synthesis in biological systems. Suitable non-natural amino acids include 3-cyclohexylalanine (Cyclohexylalanine, Cha), norleucine (Norleucine, NLe) and ornithine (Orn). Other examples of non-natural amino acids include citrulline (Cit), hydroxyproline (Hyp), 3-nitrotyrosine, nitroarginine naphtylalanine (Nal), Abu, DAB, methionine sulfoxide and methionine sulfone.

[0193] In some embodiments, the amino acid modifications result in the introduction of hydrophobic and charged surface patches in the peptide. The hydrophobic and charged surface patches can be introduced by inserting a hydrophobic and / or positively charged amino acid residue cluster (e.g., at least 3 consecutive residues), as described, for example, in Perry et al., 2018. For example, the amino acid modifications described herein can produce a c-Jun antagonist containing at least 3 consecutive amino acid residues that are lysine or leucine (e.g., in an extended hinge region and / or leucine region).

[0194] For cross-linked c-Jun antagonists, any amino acid modification (e.g., substitution) is typically located outside of the relevant position for cross-linking. That is, for an antagonist comprising cross-linking of amino acid residues b to f (in one heptad), the amino acid modification may be at position a, c, d, e, or g in the heptad. Similarly, for an antagonist comprising cross-linking of amino acid residues f to c (across two heptads), the amino acid modification may be at position a, b, c, d, or e in the first heptad and at position a, b, d, e, f, or g in the second heptad.

[0195] It is known in the art that the introduction of positively charged amino acids on the solvent-exposed face of alpha-helical peptides increases cell permeability (see, e.g., Smith et al., 2008 and Perry et al., 2018). This can be achieved by introducing arginine residues at specific positions to produce arginine substitution patterns known to promote cell permeability, as described in Smith et al., 2008. Therefore, in some embodiments, the peptides described herein comprise one or more arginine or lysine substitutions. In some embodiments, the extended hinge region and / or LZ region comprises one or more arginine or lysine modifications, i.e., arginine or lysine substitution patterns can be introduced into the peptides described herein. In some embodiments, these arginine modifications are located at positions b, c, and / or f of the heptapeptide, i.e., on the solvent-exposed face of the alpha-helical peptide.

[0196] In some embodiments, the c-Jun antagonist peptides described herein comprise a modified form of the amino acid sequence according to SEQ ID NO: 11, wherein the modification comprises one or more (e.g., one or two) of the following:

[0197] (i) the amino acid residues at positions corresponding to position 14 (position f in the heptapeptide), position 17 (position b in the heptapeptide), position 18 (position c in the heptapeptide), and position 24 (position b in the heptapeptide) are K or R residues (optionally R). For example, a c-Jun antagonist peptide may have the amino acid sequence or

[0198] (ii) the amino acid residues at positions corresponding to position 18 (position c in the heptapeptide), position 25 (position c in the heptapeptide), and position 28 (position f in the heptapeptide) are K or R residues (optionally R). For example, a c-Jun antagonist may have the amino acid sequence

[0199]

[0200] Or a variant comprising 1, 2, 3 or 4 amino acid modifications outside of said positions. Optionally, the amino acid residues at positions corresponding to SEQ ID NO: 72 or 73 at positions 31 (b in the heptapeptide) and 35 (f in the heptapeptide) are K and D amino acid residues, respectively (i.e., the amino acid modifications are at positions other than positions 14, 17, 18, 31 and 35 corresponding to SEQ ID NO: 72, or at positions other than positions 18, 25, 28, 31 and 35 corresponding to SEQ ID NO: 73).

[0201] Alternatively or additionally, the c-Jun antagonist may have an amino acid sequence having a certain degree of sequence identity with one of SEQ ID No 12 to 26. The certain degree of sequence identity may be at least 60% to 100% sequence identity. More preferably, the certain degree of sequence identity may be at least one of 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity.

[0202] Generation of antagonists

[0203] C-Jun antagonist peptides as described herein can be provided using standard synthesis or recombinant techniques in the art. Conveniently, c-Jun peptides as described herein can be produced by solid phase synthesis. Peptides are usually synthesized by solid phase synthesis in a stepwise manner from C-terminal to N-terminal. In the initial step, the amino acid of N-protection is covalently linked to an insoluble solid support by its carbonyl group. Suitable groups for N-protected amino acids include 9-fluorenylmethoxycarbonyl (Fmoc) and tert-butyloxycarbonyl (Boc). After the amino acid of covalently linked N protection, the deprotected NH2 group of the amino acid of the amino acid to be connected is removed and reacted with the carboxylic acid group of the amino acid of the next N protection to generate a nascent peptide comprising 2 amino acids covalently linked to the solid phase. Repeat this process until a complete peptide sequence is established on the solid phase. In some embodiments, protecting groups can be used to prevent the functional group in the amino acid side chain from reacting with the amino acid of the N protection introduced. These side chain protecting groups can be present in the entire building-up process of the peptide and can be removed in the final deprotection step.

[0204] A method of producing a c-Jun antagonist peptide may comprise synthesizing a peptide comprising SEQ ID NO: 1 by solid phase or liquid phase peptide synthesis.

[0205] Methods for solid phase peptide synthesis are well-known in the art (see, e.g.

[0206] Coin et al Nature Protocols 2, 3247-3256 (2007) Stawikowski (2002) CurrProtoc Protein Sci.2002 Unit-18.1.oi: 10.1002 / 0471140864.ps1801s26; Chan andWhite; Fmoc Solid Phase Peptide Synthesis-A Practical Approach.OxfordUniversity Press, 2000; Stewart, JM; Young, JDSolid-Phase Peptide Synthesis (2nd ed.), Pierce Chemical Co., Rockford, IL, 1984; Atherton, E.; Sheppard, RC, Solid-Phase Peptide Synthesis: A Practical Approach. Oxford University Press: New York City, 1989; M. Bodanzsky and A.

[0207] Bodanzsky, The Practice of Peptide Synthesis, Springer Verlag, New York (1984); JH Jones, The Chemical Synthesis of Peptides. Oxford University Press, Oxford 1991; In Applied Biosystems 430A User's Manual, ABI Inc., Foster City, California; GAGrant, (Ed.) Synthetic Peptides, A User's Guide. WH Freeman & Co., New York 1992, and GB Fields, (Ed.) Solid-Phase Peptide Synthesis (Methods in Enzymology Vol. 289). Academic Press, New York and London 1997); Merrifield, J. Amer. Chem. Soc. 85: 2149-54 (1963)).

[0208] Methods for liquid phase peptide synthesis are also well known in the art (U.S. Pat. No. 5,516,891).

[0209] The c-Jun antagonist peptides as described herein can be produced using recombinant expression. Recombinant techniques for producing peptides are standard in the art, such as described in Sambrook, J., Russel, DW Molecular Cloning, A Laboratory Manual. 3 ed. 2001, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press. The c-Jun antagonist peptides can be capped, for example, they can be capped with MAS residues at the N-terminus and capped with GAP residues at the C-terminus. The c-Jun antagonist peptides as described herein can also be further His-tagged (e.g., 6xHis-tagged).

[0210] c-Jun

[0211] The antagonist peptides described herein antagonize c-Jun. C-Jun is involved in many cellular processes, including differentiation, proliferation and survival (Shaulian et al., 2001; Eferl et al., 2003; Eckert et al., 2013; Alani et al., 1991). Human c-Jun has been well characterized in the art and may, for example, have an amino acid sequence of (UniProt Accession No. P05412, Version 2).

[0212] Peptide cross-linkers

[0213] The residues responsible for PPI present on the surface of proteins are associated with protein secondary structure motifs such as α-helices, β-sheets, and β-turns. Notably, α-helices are thought to account for approximately 60% of all secondary structures in protein complexes (Jochim and Arora, 2010). In addition, α-helices have been shown to mediate a large number of key therapeutically relevant PPI interfaces, 60% of which are bound to one face of the helix (Raj et al., 2013). α-Helices contain hydrogen bonds between the carbonyl group (C=O) of a given amino acid and the amino group (NH) of an amino acid three or four residues away.

[0214] The use of cross-linkers to constrain peptides in a helical conformation has been reported to confer benefits including enhanced protease resistance, stability in cells, improved cellular uptake, enhanced biophysical properties, and is expected to bind to its target with greater potency than the wild-type peptide sequence (Azzarito et al. 2013). α α-helical peptides (also called “helix-constrained peptides”) are of great significance for the identification of PPI inhibitors (Robertson and Spring, 2018).

[0215] Thus, in some embodiments, the c-Jun antagonist peptide compound is a helix-constrained peptide.

[0216] The term "helix-constrained peptide" is intended to mean a peptide having at least one chemical modification that results in an intramolecular crosslink between two amino acids to produce a stable alpha-helix. Typically, the crosslink extends through the length of one or two helical turns (i.e., about 3 to 3.6 or about 7 amino acids). Thus, amino acids located at i and one of i+3, i+4, and i+7 are ideal candidates for crosslinking. Thus, for example, where a peptide has the sequence ... N1, N2, N3, N4, N5, N6, N7, N8, N9 ..., and for each position, amino acid N is independently selected, crosslinking between N1 and N4, or between N1 and N5, or between N1 and N8 is useful, crosslinking between N2 and N5, or between N2 and N6, or between N2 and N9 is also useful, etc. The use of multiple crosslinks (e.g., 2, 3, 4, or more) is also contemplated. Thus, as used herein, a helix-constrained peptide comprises at least one crosslinker between two amino acid residues.

[0217] Chemical modifications include those that incorporate molecular tethers (eg, hydrocarbon staples) and those that promote disulfide bridge formation. The cross-links may be ionic, covalent or hydrogen bonds linking two residues together, preferably the cross-links are covalent bonds.

[0218] The presence of stabilized α-helices can be determined using methods such as circular dichroism spectroscopy for α-helices, such as in Jo et al. (2012), as described in the Examples herein. Circular dichroism can be used to measure the increase in helicity, i.e., linear to cyclic. In cases where cross-linking occurs by forming a disulfide bridge between two thiol groups, such as between two cysteine ​​residues, the presence of stabilized α-helices can also be determined using an assay that determines whether the thiol in the sample is free or conjugated. For example, free thiols can be determined by reacting with Ellman's reagent (5,5′-dithiobis(2-nitrobenzoic acid; DNTB) (Sigma)) and monitoring the absorbance at 412 nm.

[0219] Methods for inducing cross-links between amino acids are well known and include methods for inducing cross-links between peptide backbones, for example, between carbonyl and amino groups as in a native α-helix, and between side chains of peptides.

[0220] Cross-linking agents include disulfide bonds (e.g., as described in Leduc et al. (2003)), hydrogen bond surrogates (e.g., as described in Wang et al. (2005)), ring closing metathesis (e.g., as described in Walensky et al. (2004)), cysteine ​​alkylation using α-haloacetamide derivatives (e.g., as described in Woolley (2005)) or biaryl halides (e.g., as described in Muppidi et al. (2011)), lactam rings (e.g., as described in Fujimoto et al. (2008)), hydrazine linkages (e.g., as described in Cabezas & Satterthwait (1999)), oxime linkages (e.g., as described in Haney et al. (2011)), metal chelation (e.g., as described in Ruan et al. (2012)). et al. (1990)) and "click" chemistry (e.g., as described in Holland-Nell & Meldal (2011)).

[0221] Cross-linking agents can be used to cross-link cysteine ​​residues. Thus, the peptide may contain cysteine ​​(C) at positions i and i+4 or i and i+7 in its amino acid sequence. As described in Jo et al. (2012), it is useful to introduce cysteine ​​residues at positions i and i+4 because this spacing brings two thioether residues close together when in an α-helix. Suitable cross-linking agents for stabilizing α-helices in peptides containing cysteine ​​(C) at positions i and i+4 are described in Jo et al. (2012). For example, the cross-linking agent may be a cross-linking agent selected from alkyl bromides, alkyl iodides, benzyl bromide, allyl bromide, maleimide and electrophilic difluorobenzene. Suitable cross-linking agents for cross-linking cysteine ​​are known in the art (see, for example, Fairlie & Dantas de Araujo, 2016 and Jo et al., 2012).

[0222] In some embodiments, the crosslinking agent is m-xylene-based, o-xylene-based, or p-xylene-based benzyl bromide, more preferably m-xylene-based benzyl bromide.

[0223] In some embodiments, the cross-linking agent is a compound of Formula 1:

[0224]

[0225] in

[0226] n is an integer selected from 1 to 3;

[0227] m is an integer selected from 0 to 2;

[0228] A is selected from C 2-6-Alkenylene, C 5-12 -Arylene and C 5-12 -heteroarylene;

[0229] Y is a covalent bond, C 1-6 Alkylene or -N(H)C(=O)CH2-;

[0230] R 1 is selected from Cl, Br, I or F; and

[0231] Each L is independently selected from -C(=O)-, -C≡C-, -N=N-, C 1-6 Alkylene and covalent bonds.

[0232] R 1 The A group provides a reactive group (e.g., a leaving group) for reacting with cysteine. When cross-linked by two derivatizable amino acid residues, the A group provides a structure suitable for conformationally constraining the peptide in a call to the linker. For example, the A group can be conformationally constrained to a geometric shape suitable for connecting two derivatizable amino acid residues. In some embodiments, R 1 is Br. In some embodiments, A is selected from C 5-12 -Arylene and C 5-12 -heteroarylene. In some embodiments, m is 0. In some embodiments, Y is methylene. In some embodiments, L is a covalent bond.

[0233] In some preferred embodiments, the crosslinking agent is 1,3-dibromomethylbenzene (DBMB) having the following chemical formula:

[0234]

[0235] DBMB can be used to react with the derivatizable amino acid residues at positions i and i+3 or i and i+4 in the amino acid sequence of the peptide.

[0236] In some preferred embodiments, the crosslinking agent is 4,4'-dibromomethyl-biphenyl (4,4'-bisbromomethyl-biphenyl, Bpy) having the following chemical formula:

[0237]

[0238] Bpy can be used to react with derivatizable amino acid residues at positions i and i+7 in the amino acid sequence of the peptide.

[0239] The cysteine ​​residues in the cross-linked peptides can be cross-linked using known methods, such as those described in Timmerman et al., 2005 or WO 2021 / 260074. In short, the method may include reacting a cross-linking agent (e.g., DBMB) with the peptide in the presence of tris (2-carboxyethyl) phosphine (TCEP) and ammonium bicarbonate, and reacting in the dark for 4 to 5 hours at pH 8.0 and room temperature. The method may be performed in vitro or in cells. Intracellular methods may include providing cells (e.g., bacterial cells, such as Escherichia coli cells, or eukaryotic cells, such as human cells) containing recombinant peptides, contacting the cells with a cross-linking agent (e.g., as part of a cell culture medium), and culturing the cells in the presence of a cross-linking agent. The cross-linking agent may be present at a concentration of 1 μM to 1 mM (e.g., 10 μM to 100 μM) and for a period of at least 20 minutes (e.g., 20 minutes to 10 hours). Additional details of suitable intracellular cross-linking methods are provided, for example, in WO 2021 / 260074.

[0240] The cross-linking agent forms a thioether cross-link with at least one pair of cysteines, such that the c-Jun antagonist may comprise the following structure:

[0241]

[0242] Y, L, R 1 , n, m and A are as defined for Formula 1. 1a represents a CH2-CH2-linker or bond derived from a suitable R1 group in formula 1.

[0243] In some embodiments where the alkyl cross-link formed between two C residues is formed by DBMB, the c-Jun antagonist may comprise the following structure:

[0244]

[0245] The cross-linking agent can be used to cross-link lysine (K) and aspartic acid (D) in the peptide. Thus, the peptide may contain lysine (K) and aspartic acid (D) at positions i and i+4 of its amino acid sequence. That is, position i is lysine (K) and position i+4 is aspartic acid (D), or position i is aspartic acid (D) and position i+4 is lysine (K). For example, K may be at b in one heptapeptide and D at f, or K may be at f in one heptapeptide and D at c in the subsequent heptapeptide.

[0246] Lactamization is useful in terms of biological stability because proteases generally recognize β-strands, where the constraint provides further steric blocking, denies access to the main chain (Tyndall JD et al., 2005), and has potential bioavailability and membrane permeability due to the lipophilicity of the constraint. A lactam bridge in a peptide refers to an amide bond formed between the side chain of lysine (K) and the side chain of glutamic acid (E) or aspartic acid (D), typically aspartic acid (D). Methods for performing KD lactamization are described in the Examples herein and, for example, in de Araujo et al. (2014).

[0247] As described above, crosslinks can be formed between amino acids at positions i and i+3, i and i+4, or i and i+7 in the amino acid sequence of the peptide. In some embodiments, crosslinks are formed between cysteine ​​(C) residues at these positions. In other embodiments, crosslinks are formed between lysine (K) and aspartic acid (D) residues at these positions. Preferably, crosslinks are formed between amino acids at positions i and i+4.

[0248] Nucleic Acids

[0249] In the present specification, the nucleic acid encoding the c-Jun antagonist peptide may be any nucleic acid (DNA or RNA).

[0250] Conjugate

[0251] In some embodiments, the c-Jun antagonist may be conjugated to another moiety, such as a fatty acid or other lipid, a polymer, or another peptide sequence (e.g., a cell penetrating peptide (CPP)), optionally via a linker. Such a conjugate retains the functional antagonist properties of the c-Jun antagonist and may have one or more improved properties, such as stability, half-life in vivo or potency or cell permeability, relative to the unconjugated c-Jun antagonist. The moiety may be conjugated to the c-Jun antagonist via the N- or C-terminus of the peptide or any other site.

[0252] In some embodiments, the peptide can be conjugated to a cell penetrating peptide (CPP). CPP is a class of peptides that can penetrate the plasma membrane of mammalian cells and can transport compounds of various types and molecular weights across the membrane. When CPP is chemically linked or fused to other proteins, the resulting polypeptide is able to enter the cell. The connection to the CPP can be direct (e.g., as part of a fusion protein) or can be through a linker (e.g., a short peptide linker). CPPs are typically peptides of less than 30 amino acids, derived from natural or non-natural proteins or chimeric sequences. Some examples of CPPs include tat Penetrate Transporter VP-22 Pep-1 MAP SAP Oligo-arginine or Calcitonin SynB

[0253] and Pvec These and other suitable CPPs are described in Heitz et al. 2009.

[0254] In some embodiments, the peptide can be conjugated to a lipid. Peptide lipidation is an effective strategy to change the pharmacokinetics, pharmacodynamics, and cell penetration properties of peptide therapeutics, and has been shown to be successful for several therapeutic peptides. Cholesterol and fatty acids of various chain lengths, such as C8-octanoic acid, C12-lauric acid, and C16-palmitic acid are commonly used as lipid motifs, which are covalently linked to peptide inhibitors via ester, ether, amide, or carbamate bonds. Some examples of peptide lipidation are described in Kowalczyk et al. 2017.

[0255] Pharmaceutical composition

[0256] Functionally active antagonists of c-Jun of the present invention can be used to inhibit c-Jun in a therapeutic setting. Thus, the c-Jun antagonist peptides of the present invention can be formulated in a pharmaceutical composition.

[0257] A pharmaceutical composition is a formulation comprising one or more active agents (eg, a c-Jun antagonist peptide or conjugate described herein) and one or more pharmaceutically acceptable excipients. The pharmaceutical composition may be capable of inducing a therapeutic effect.

[0258] The pharmaceutical composition may comprise the c-Jun antagonist peptide or conjugate of the present invention and a pharmaceutically acceptable excipient or carrier.

[0259] The method of preparing the pharmaceutical composition may comprise: mixing the c-Jun antagonist peptide or conjugate as described above with a pharmaceutically acceptable excipient.

[0260] The term "pharmaceutically acceptable" refers to compounds, materials, compositions and / or dosage forms that are, within the scope of sound veterinary or medical judgment, suitable for use in contact with the tissues of a subject (e.g., a human or other mammal) without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit / risk ratio. Each carrier, excipient, etc. must also be "acceptable" in the sense of being compatible with the other ingredients of the formulation.

[0261] Suitable excipients and carriers include, but are not limited to, water, saline, buffered saline, phosphate buffer, alcohol / aqueous solution, emulsion or suspension. Other conventionally used diluents, adjuvants and excipients can be added according to conventional techniques. Such carriers can include ethanol, polyols and suitable mixtures thereof, vegetable oils and injectable organic esters. Buffers and pH regulators can also be used, and include, but are not limited to, salts prepared from organic acids or bases. Representative buffers include, but are not limited to, organic acid salts, such as citrate (e.g., citrate), ascorbate, gluconate, carbonate, tartrate, succinate, acetate, phthalate, Tris salt, trimethylamine hydrochloride or phosphate buffer. Parenteral carriers can include sodium chloride solution, Ringer's dextrose, dextrose, trehalose, sucrose, lactated Ringer's solution or fixed oil. Intravenous carriers can include fluid and nutrient supplements, electrolyte supplements, such as those based on Ringer's dextrose, etc. Preservatives and other additives, such as antimicrobial agents, antioxidants, chelating agents (e.g., EGTA; EDTA), inert gases, etc., may also be provided in the pharmaceutical carrier. The pharmaceutical compositions described herein are not limited by the choice of carrier. It is within the skill of the art to prepare these pharmaceutical compositions with suitable pH, isotonicity, stability and other conventional characteristics from the above components.

[0262] Suitable carriers, excipients and the like can be found in standard pharmaceutical textbooks, for example, Remington's Pharmaceutical Sciences and The Handbook of Pharmaceutical Excipients' 4th edit., eds. RC Rowe et al, APhA Publications, 2003.

[0263] The term "carrier" refers to diluents, binders, lubricants and disintegrants. Those skilled in the art are familiar with such pharmaceutical carriers and methods of using such carriers to formulate pharmaceutical compositions.

[0264] The pharmaceutical composition may conveniently be presented in unit dosage form and may be prepared by any method known in the pharmaceutical art. Such methods include the step of associating the peptide with a carrier or excipient as described above, which may constitute one or more auxiliary ingredients. In general, the formulation is prepared by uniformly and intimately associating the active compound with a liquid carrier or a finely divided solid carrier or both.

[0265] The pharmaceutical compositions described herein can be produced in a variety of forms according to the route of administration. The pharmaceutical composition can be prepared for administration to a subject in the form of, for example, a liquid, powder, aerosol, tablet, capsule, enteric coated tablet or capsule, or suppository. The pharmaceutical composition can also be in the form of a suspension, solution, emulsion in an oily or aqueous carrier, paste, and implantable sustained release or biodegradable preparation. Compositions for sustained release or implantation may include pharmaceutically acceptable polymers or hydrophobic materials, such as emulsions, ion exchange resins, slightly soluble polymers, or slightly soluble salts. The pharmaceutical composition can be prepared in the form of a sterile aqueous solution or dispersant suitable for injectable use, or prepared in a lyophilized form using freeze drying technology. The lyophilized pharmaceutical composition is usually kept at about 4°C and can be reconstituted in a stable solution (e.g., saline or HEPES) with or without an adjuvant. The pharmaceutical composition can also be prepared in the form of a suspension or emulsion.

[0266] The pharmaceutical compositions may be presented in unit-dose or multi-dose sealed containers such as ampoules and vials and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of a sterile liquid carrier, such as water for injection, immediately prior to use.

[0267] The pharmaceutical composition can be administered to a subject by any convenient route of administration. In some embodiments, administration is by systemic routes, including oral, or more preferably parenteral routes. For example, the pharmaceutical composition can be administered by intravenous, intraperitoneal or subcutaneous injection.

[0268] Treatment of disease

[0269] c-Jun plays a role in many cellular processes such as differentiation, proliferation and survival, and thus dysregulation of this transcription factor can lead to a range of human diseases. Therefore, the c-Jun antagonist peptides, nucleic acids, conjugates or pharmaceutical compositions described herein can be used in methods of treating animals or humans, for example, in methods of treating c-Jun mediated diseases in individuals in need thereof.

[0270] An individual with a c-Jun mediated disease may exhibit at least one recognizable sign, symptom, or laboratory finding sufficient to be diagnosed as a c-Jun mediated disorder according to clinical criteria known in the art. Some examples of such clinical criteria can be found in medical textbooks such as Harrison's Principles of Internal Medicine, 15th Ed., FauciAS et al., eds., McGraw-Hill, New York, 2001. In some embodiments, the individual may have been previously identified or diagnosed with a c-Jun mediated disorder, or the methods of the invention may comprise identifying or diagnosing the presence of a c-Jun mediated disorder in an individual, predicting a c-Jun mediated disorder in an individual, or assessing the risk of onset of a c-Jun mediated disorder.

[0271] Treatment can be any treatment or therapy, whether for humans or animals (e.g., in veterinary applications), in which some desired therapeutic effect is achieved, such as inhibition or delay of progression of a c-Jun mediated disease, and including reduction in the rate of progression, arrest of the rate of progression, amelioration of a c-Jun mediated disease, cure or alleviation (whether partial or total) of a c-Jun mediated disease; prevention, delay, alleviation or arrest of one or more symptoms and / or signs of a c-Jun mediated disease, or prolonging the survival of a subject or patient beyond that expected in the absence of treatment.

[0272] Also included is treatment as a preventative measure (i.e., prevention) (e.g., treatment prior to the onset of a disorder in an individual to reduce the individual's risk of developing the disorder; delay its onset; or reduce its severity after onset). For example, an individual who is susceptible to a c-Jun-mediated disease (e.g., cancer) or is at risk of developing or recurring a c-Jun-mediated disease can be treated as described herein. Such treatment can prevent or delay the onset or recurrence of a c-Jun-mediated disease or one or more symptoms thereof in an individual.

[0273] The c-Jun antagonist peptides may be used in methods of treating any of the following diseases: cancer, diabetes, cardiovascular disease, autoimmune disease, joint disorders (eg, arthritis), and neurodegenerative diseases.

[0274] "Cancer" may include any one or more of the following: acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), adrenocortical carcinoma, anal cancer, bladder cancer, blood cancer, bone cancer, brain tumor, breast cancer, female reproductive system cancer, male reproductive system cancer, central nervous system lymphoma, cervical cancer, childhood rhabdomyosarcoma, childhood sarcoma, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), leukemia, CML), colorectal cancer, colon cancer, endometrial cancer, endometrial sarcoma, esophageal cancer, eye cancer, gallbladder cancer, stomach cancer, gastrointestinal cancer, hairy cell leukemia, head and neck cancer, hepatocellular carcinoma, Hodgkin's disease, hypopharyngeal cancer, Kaposi's sarcoma, kidney cancer, laryngeal cancer, leukemia, leukemia, liver cancer, lung cancer, malignant fibrous histiocytoma, malignant thymoma, melanoma, mesothelioma, multiple myeloma, myeloma, nasal and paranasal sinus cancer, nasopharyngeal cancer, nervous system cancer, neuroblastoma tumors, non-Hodgkin lymphoma, oral cancer, oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pituitary tumors, plasma cell tumors, primary CNS lymphoma, prostate cancer, rectal cancer, respiratory system, retinoblastoma, salivary gland cancer, skin cancer, small intestine cancer, soft tissue sarcoma, stomach cancer, gastric cancer, testicular cancer, thyroid cancer, urinary system cancer, uterine sarcoma, vaginal cancer, vascular system, Waldenstrom's macroglobulinemia, and Wilms' tumor.

[0275] The cancer can be of a specific type. Some examples of cancer types include astrocytoma, carcinoma (e.g., adenocarcinoma, hepatocellular carcinoma, medullary carcinoma, papillary carcinoma, squamous cell carcinoma), glioma, lymphoma, medulloblastoma, melanoma, myeloma, meningioma, neuroblastoma, sarcoma (e.g., angiosarcoma, chondrosarcoma, osteosarcoma).

[0276] In some embodiments, after initial cancer treatment, an individual may have minimal residual disease (MRD).

[0277] Cancer treatment may include inhibiting cancer growth, including complete remission of cancer; and / or inhibiting cancer metastasis. Cancer growth generally refers to any of a number of indicators that indicate a change in the cancer to a more advanced form. Thus, indicators for measuring cancer growth inhibition include a reduction in cancer cell survival, a reduction in tumor volume or morphology (e.g., as determined using computed tomographic (CT), ultrasound or other imaging methods), a delay in tumor growth, a disruption of tumor vasculature, an improvement in performance in a delayed hypersensitivity skin test, an increase in T cell activity, and a reduction in tumor-specific antigen levels.

[0278] In some embodiments, c-Jun antagonist peptides can be used to inhibit or reduce metastasis of cancer. For example, a method of reducing or inhibiting metastasis in an individual with cancer may include administering a therapeutically effective amount of a c-Jun peptide to the individual.

[0279] A subject suitable for treatment as described above can be a mammal, such as a rodent (e.g., guinea pig, hamster, rat, mouse), murine (e.g., mouse), canine (e.g., dog), feline (e.g., cat), equine (e.g., horse), primate, simian (e.g., monkey or ape), monkey (e.g., marmoset, baboon), ape (e.g., gorilla, chimpanzee, orang-utan, gibbon), or human.

[0280] In some preferred embodiments, the subject is a human. In other preferred embodiments, non-human mammals may be used, particularly mammals that are commonly used as models for demonstrating therapeutic efficacy in humans (e.g., murine, primate, porcine, canine, or rabbit animals).

[0281] The methods according to the invention may be performed in vitro, ex vivo or in vivo, or the products may be present in vitro, ex vivo or in vivo. The term "in vitro" is intended to cover experiments performed using materials, biological substances, cells and / or tissues under laboratory conditions or in culture, while the term "in vivo" is intended to cover experiments and manipulations performed using intact multicellular organisms. "Ex vivo" refers to something that exists or occurs outside an organism (e.g., outside the human or animal body), which may be on a tissue (e.g., a whole organ) or a cell taken from an organism.

[0282] When the method is performed in vitro, it may comprise a high throughput screening assay.The test compound used in the method may be obtained from a synthetic combinatorial peptide library, or may be a synthetic peptide or peptidomimetic molecule.

[0283] ***

[0284] Features disclosed in the foregoing description, or in the appended claims, or in the drawings, in their specific form, or in terms of a manner for performing a disclosed function, or a method or process for obtaining a disclosed result, may be used, as appropriate, separately or in any combination of such features, to implement the invention in its multiple forms.

[0285] Although the present invention has been described in conjunction with the above exemplary embodiments, many equivalent modifications and variations will be apparent to those skilled in the art when considering the present disclosure. Therefore, the exemplary embodiments of the present invention set forth above are considered to be illustrative and not restrictive. Various changes may be made to the embodiments without departing from the spirit and scope of the present invention.

[0286] For the avoidance of any doubt, any theoretical explanations provided herein are provided for the purpose of improving the reader's understanding. The inventors do not wish to be bound by any of these theoretical explanations.

[0287] Any section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0288] Throughout this specification (including the appended claims), unless the context requires otherwise, the words "comprise" and "comprising" and variations thereof will be understood to imply the inclusion of stated integers or steps or groups of integers or steps but not the exclusion of any other integers or steps or groups of integers or steps.

[0289] It must be noted that nouns as used in the specification and the appended claims without quantifiers include plural referents unless the context clearly indicates otherwise. Ranges may be expressed herein as from "about" one particular value, and / or to "about" another particular value. When such a range is expressed, another embodiment includes from the one particular value and / or to the other particular value. Similarly, when a value is expressed as an approximation by using the antecedent "about," it will be understood that the particular value forms another embodiment. The term "about" in relation to a numerical value is optional and means, for example, + / - 10%.

[0290] sequence

[0291]

[0292]

[0293]

[0294]

[0295]

[0296] Example

[0297] Certain aspects and embodiments will now be illustrated by way of example and with reference to the above-identified drawings.

[0298] Example 1 - Identification of functional peptide antagonists

[0299] Many rational design approaches, library screening, and selection systems exist and have led to the successful identification of molecules capable of binding to a given TF target, but a key challenge remains to ensure that target binding will translate into ablation of function (Brenna et al., 2020; Baxter et al., 2014). Multiple approaches have generated peptide-based c-Jun antagonists that target a broad range of LZ binding interfaces (Boysen et al., 2002; Mason et al., 2006; Kaplan et al., 2014; Baxter et al., 2017; Lathbridge et al., 2018). However, it is difficult to predict whether LZ binding will translate into functional antagonism because the c-Jun DBD remains unbound and is able to bind TRE DNA (Seldeen et al., 2008; Szalóki et al., 2015). Rationally designed peptides have been shown to target cJun DBDs, but exhibit lower potency than LZ antagonists and raise concerns about specificity due to the high sequence similarity between AP-1 family DBDs (Tsuchida et al 2004). Similarly, a series of SMs targeting TRE DNA have been developed (Dai et al., 2004; Fanjul et al., 1994), but these are also less potent and have the potential to produce off-target effects, as multiple TFs typically bind to any given DNA element, with some bZIP / DNA combinations known to promote anticancer outcomes (Eferl et al., 2003; Rodríguez-Martínez JA et al., 2017). One way to circumvent the potential drawbacks of these approaches is to utilize longer peptides that target the entire c-Jun bZIP domain with selective but high-affinity interactions, simultaneously blocking both DNA binding and LZ dimerization. Olive et al. used this method to produce A-Fos, which combined wild-type (WT) cFos LZ (known to heterodimerize with c-Jun) and a rationally designed Glu-rich acidic extension (Figure 1) (Olive et al., 1997). The A-Fos design principle assumes that the LZ interaction extends at the N-terminus, resulting in a DBD-acidic extension interaction promoted by incorporating Leu residues into the putative d position in the acidic extension. An intracellular transcription blocking survival (TBS) library screening assay was developed and validated to retrieve functional TF antagonists, in which cell survival occurs only when TF activity is eliminated. In addition, bacterial growth rate is correlated with antagonist efficiency, allowing comparison and competition between TF antagonists.Here, we demonstrate methods using large peptide libraries (131,027 members) showing that they can be screened for functional cJun antagonism within the TBS platform. Selected peptides were validated using a battery of biophysical methods, demonstrating clear improvements over the parent peptide in both target binding and c-Jun / TRE DNA antagonism, which was particularly facilitated by reduced homodimer stability. The following methods were used:

[0300] 1.1 Methods

[0301] Plasmid construction and protein production: TRE-mDHFR ( Figure 2 ) and WT-mDHFR DNA constructs were subcloned into pQE16-derived plasmid pES300d; c-Jun LZ and c-Jun bZIP DNA constructs were subcloned into pQE16-derived plasmid pES230d; and cFos LZ and A-FosW DNA constructs were subcloned into pET24a. The human c-Jun bZIP domain was derived from Arg 252 Cross to Leu 308 , and the LZ domain is derived from Ile 277 Cross to Leu 308 The human cFos bZIP domain is derived from Glu 137 Cross to Leu 193 , and the LZ domain is derived from Thr 162 Cross to Leu 193 . A-FosW has the following sequence:

[0302] (FosW sequence is shown in bold). All constructs were capped at the N-terminus with AS residues and at the C-terminus with GAP residues and were also 6×His tagged, except for WT-mDHFR or TRE-mDHFR constructs which were only 6×His tagged. Table 1 provides a complete sequence listing.

[0303] Table 1: Prior art and Hinge W peptide sequences

[0304]

[0305] Proteins were purified by subcloning the DNA sequence of the protein into pET21-His-SUMO plasmid (cJun bZIP, cFos bZIP) or pET24a plasmid (HingeW, A-FosW, FosW) using NheI and AscI sites. Overnight cultures of E. coli containing the relevant plasmids were used to inoculate LB medium at a dilution factor of 1:1000. The cultures were incubated under shaking (37°C, 200 rpm) until OD600nm Reach 0.7. Protein overexpression was induced by adding IPTG (1 mM), followed by overnight incubation under shaking (25°C, 200 rpm). Cells were then harvested from the culture by centrifugation. The cell pellet was resuspended in Histrap binding buffer (20 mM potassium phosphate, 500 mM NaCl, 40 mM imidazole, 5 mM DTT, pH 7.4), sonicated and loaded on a HisTrap HP 5 mL preloaded column. The column was washed with binding buffer, and the protein sample was then eluted on a binding buffer: elution buffer (20 mM potassium phosphate buffer, 500 mM NaCl, 400 mM imidazole, 5 mM DTT, pH 7.4) gradient. This method was also used to produce approximately 80% pure His-tagged ULP1 protease samples for the SUMO cleavage step. The SUMO-tagged protein was buffer exchanged into a standard buffer (20 mM Tris.HCl, 2 mM DTT, pH 8.0). A 10:1 mixture of SUMO-tagged protein:ULP1 was incubated at 30°C for 16 hours. Since the SUMO-tagged construct was His-tagged at the N-terminus on SUMO, the cleavage reaction was diluted 1:5 in binding buffer and then passed through a HisTrap column to remove the cleaved SUMO tag and His-tagged ULP1. The final PCR product was purified by using a Jupiter Proteo column (4-μm particle size, The HisTrap effluent was purified to >98% purity using a water:acetonitrile gradient (0.1% TFA) using RP-HPLC with a pore size of 250×10 mm; Phenomenex. Peptides without the SUMO tag were concentrated after Histrap elution and subjected to HPLC purification. Peptide purity and identity were verified by SDS-PAGE and electrospray ionization mass spectrometry.

[0306] DHFR activity assay: The activity of the purified DHFR enzyme was measured using a colorimetric assay kit (Sigma CD0340). WT-mDHFR or TRE-mDHFR (100 nM in the reaction) and NADPH (60 μM in the reaction) were mixed in the assay buffer alone or with the DHFR inhibitors TMP or Mtx (1 μM in the reaction). The reaction was initiated by adding DHF (50 μM in the reaction plus a blank reaction without DHF) and the absorbance of the samples was measured at 340 nm using a Varian Cary 50 UV-Vis spectrophotometer. The specific activity was calculated using the following equation:

[0307] Library construction and TBS assay: Library inserts were generated using PCR fill-in reactions from synthetic primers (Sigma) with degenerate codons at the desired positions to generate the correct residue options. The library was subcloned into the pET24a plasmid containing A-FosW using Sad and AscI sites. The primers used were cJun-Hinge-Lib-F: 5'- and cJun-Hinge-Lib_R:5'- The library DNA was transformed into NEB 10-β electrocompetent E. coli cells. The library coverage was determined by the number of single colonies using the following equation: Wherein E is the percentage of deletion library, m is the number of colonies collected and n is the library size. This shows that from the 2155000 library colonies collected, 99.9% of the hinge library is covered. Library DNA quality is assessed by sequencing both the DNA pool and many single colonies to show the degenerate codons in the correct position in the pool and to show the diversity of library members from single colonies. The library DNA pool is transformed into BL21 Gold cells containing pES300d-TRE-mDHFR and pES230d-cJun bZIP.

[0308] Selective pressure was applied by growing the bacteria in M9 minimal medium with TMP (2 to 4 μM) as well as ampicillin, kanamycin, and chloramphenicol to maintain the desired plasmids and IPTG (1 mM) to induce protein expression. Library transformants were first plated onto selective agar plates (2 μM TMP) and incubated at 37°C for 72 to 96 hours. Optimization experiments ( Figure 5 ) indicated that 4 μM TMP was optimal for selection, however lower stringency was used initially and then selection was increased in subsequent steps. Colonies from this first round of selection were pooled and plated in liquid culture at a starting OD of 0.05. 600 The cells were continuously cultured at 37°C with shaking at 200 rpm until OD 600Reach 0.6. The TMP concentration was 2 μM in the first liquid culture passage, and then it was increased to an optimal 4 μM in subsequent passages. Bacteria containing the most effective functional antagonists are expected to produce higher levels of TRE-mDHFR, which provides a growth advantage, and these will dominate the culture. At each passage step, samples of the culture were plated on LB agar (supplemented with antibiotics to maintain the plasmid) to select and sequence individual colonies, and the DNA pool was also sequenced. This allows the appearance of library members to be monitored when the winning sequence is selected. The assay validation experiment utilized an improved assay method, whereby an overnight culture of a glycerol stock from a control strain (Table 2) was diluted to OD 600 =0.5, and 50 μL was plated on selective M9 minimal medium agar plates.

[0309] Table 2: E. coli control strains showing TBS assay validation of inserts expressed from each plasmid.

[0310] Strains used for growth experiments were plasmid-matched to ensure equivalent antibiotic pressure, with scrambled protein sequences used in unwanted plasmids.

[0311] pES300d pES230d pET24a 1 WT-mDHFR Out of order (cJun bZIP) Out of order (A-FosW) 2 WT-mDHFR cJun bZIP Out of order (A-FosW) 3 TRE-mDHFR Out of order (cJun bZIP) Out of order (A-FosW) 4 TRE-mDHFR LZ Out of order (A-FosW) 5 TRE-mDHFR cJun bZIP Out of order (A-FosW) 6 TRE-mDHFR cJun bZIP LqCy 7 TRE-mDHFR cJun bZIP FWf 8 TRE-mDHFR cJun bZIP A-FosW 9 TRE-mDHFR cJun bZIP HingeW

[0312] Circular Dichroism (CD): CD measurements were performed using an Applied Photophysics Chirascan with 200 μL samples in a 1 mm path length CD cell. Protein / DNA samples were suspended in 150 mM potassium phosphate, 150 mM potassium fluoride, and 5 mM TCEP at pH 7.4 and equilibrated for 30 min prior to measurement. For the full spectrum, three scans were collected between 190 and 260 nm (265 to 320 nm for DNA binding experiments) with a 1 nm bandwidth and were acquired with a 0.5 s -1 The data were collected at a rate of . These scans were averaged and converted to molar residue ellipticity (MRE). Thermal denaturation experiments were performed by measuring the ellipticity at 222 nm in a gradient of 1 to 90°C with 1°C increments. The post-melting scan at 20°C determined that the transitions were reversible because they overlapped within 10% of the scan before melting. The resulting thermal denaturation curves were converted to MRE and fitted to a two-state model derived by modifying the Gibbs-Helmholtz equation to determine the melting temperature (Tm) (Mason et al., 2007).

[0313] Isothermal Titration Calorimetry (ITC): Peptides were studied in ITC buffer, pH 7.4, consisting of 10 mM potassium phosphate, 150 mM potassium fluoride, and 5 mM TCEP. Using a MicroCal VP-ITC instrument (Malvern), 10 μL injections of 10 μM antagonist peptide were injected into cells containing 1 μM cJun. MicroCal Origin software was used to record and analyze the thermal changes after addition. Control experiments involved injecting antagonist peptide samples into cells containing ITC buffer alone to determine the subtracted heat of dilution. The resulting binding data were fit to a one-site binding model to extract the enthalpy change (ΔH) and equilibrium binding constant (K) of binding. D ), from which the free energy change of binding (ΔG) and the entropy change of binding (ΔS) were calculated (Wiseman et al., 1989). Thermodynamic parameters are expressed as the mean of two independent experiments, with the error expressed as one standard deviation.

[0314] Electrophoretic Mobility Shift Assay (EMSA): The following double-stranded oligonucleotide sequences were used: Control non-TRE: (Sigma). Complementary single strands of DNA were purchased (Sigma) and mixed in a 1:1 ratio, then heated to 95°C for 20 minutes and then slowly cooled to room temperature to form DNA duplexes. Protein / DNA samples for electrophoresis were incubated in binding buffer (150 mM KCl, 1 mM dithiothreitol, 1 mM EDTA, 10 mM Tris, 10 mM MgCl2, pH 8) at 4°C for 30 minutes and then run on a 1.3% agarose gel in 0.5×TBE buffer (supplemented with 10 mM MgCl2). Green dye is included in the gel and running buffer to stain the DNA, which is imaged on a transilluminator and then added Ruby and incubated for 3 hours to stain proteins. The gel was destained in 10% methanol, 7% acetic acid solution for 1 hour and then imaged on a transilluminator. 1.2 Generation of active mDHFR from TRE-containing genes to promote transcriptional blockade imposed by c-Jun

[0315] Transcriptional blocking survival (TBS) is an intracellular assay that uses cell survival as a readout. This allows screening of protein-DNA interaction antagonists and identifies the most active antagonists by their ability to remove transcriptional blocking of exogenous murine dihydrofolate reductase (DHFR). This enzyme is absolutely essential for survival because it is necessary for the production of purines required for DNA and amino acid synthesis. Endogenous E. coli DHFR (ecDHFR) can be selectively inhibited by trimethoprim (TMP), which means that the survival of cells grown in M9 minimal medium is dependent on exogenous murine DHFR (mDHFR) activity (Matthews et al., 1985). We generated the mDHFR gene ( Figure 2 3) to introduce 15 TRE sites into the coding DNA sequence to allow robust cJun transcriptional blocking while minimizing the change to the expressed protein (TRE-mDHFR). In particular, the resulting TRE-mDHFR construct was produced by two silent mutations and thirteen conservative mutations. Using the WT-mDHFR crystal structure as a design guide (PDB code: 1U72) (Cody et al., 2005), it was not considered that 7,8-dihydrofolate (7,8-dihydrofolate, DHF) substrates or nicotinamide adenine dinucleotide phosphate (NADPH) cofactors (e.g., A10, L23, W25 and R71) were combined with important residues to be changed (Cody et al. 2005; Tillet et al. 1988). The accessible surface areas of all other amino acid residues were calculated using the “Accessible Surface Area and Accessibility Calculation for Protein” tool (http: / / cib.cf.ocha.ac.jp / bitool / ASA / ). A cutoff score of , below which residues are considered buried due to solvent exposure and therefore more likely to be disruptive if altered. Of the remaining non-essential, surface-exposed residues, mutations were allowed only if the R group changes were relatively conservative. The precise allowed substitutions included to be incorporated into the TRE site are as follows: F32S, T40Q, S42D, G46S, K64S, R78Q, Q103S, M112S, N127T, R138Q, L154S, Y163S, and E169Q.

[0316] 1.3 Establishment of transcription blockade survival assay

[0317] We first sought to determine whether the new TRE-mDHFR construct could replace TMP-inhibited ecDHFR by confirming its expression, folding, and catalytic activity. This was achieved by: i) SDS-PAGE analysis of cell lysates, confirming that the protein was expressed in the soluble fraction after induction with isopropyl β-D-1-thiogalactopyranoside (IPTG) (Figure 4), ii) plating E. coli containing the TRE-mDHFR plasmid on M9 agar supplemented with TMP; no growth was observed (4 μM TMP, in Figure 5 ), where growth was restored after induction of TRE-mDHFR expression by IPTG ( Figure 5 and 8B -3), and iii) by tracking the reduction of NADPH at 340nm in the presence of DHF substrate to monitor the activity of recombinant WT-mDHFR and TRE-mDHFR of purification (Fig. 3). The specific activity calculated from these reactions shows that the activity of TRE-mDHFR is reduced by 24 times relative to WT. In addition, in the presence of TMP, TRE-mDHFR shows that the specific activity is reduced by about 1.8 times, while WT-mDHFR is unaffected. Although it is expected that the activity is reduced due to thirteen amino acid replacements, TRE-mDHFR retains its ability to convert DHF and confer survival (while ecDHFR is impaired), confirming its suitability for TBS.

[0318] Having established that TRE-mDHFR is active under selective conditions (M9 minimal medium + 4 μM Tmp + 1 mM IPTG) and is absolutely required for cell survival, we next expressed the cJun bZIP domain in cells containing the TRE-mDHFR plasmid, which resulted in a 21-fold decrease in colony counts ( P ≤ 0.0001; Figure 8B-5 In the presence of WT-mDHFR (i.e., lacking the essential TRE binding site), expression of cJun bZIP reduced bacterial proliferation (P ≤ 0.05, Figure 8B -1 vs 8B-2). This may be due to nonspecific binding of overexpressed cJun to plasmid DNA. However, transcriptional blockade was strongly TRE site specific, as shown by a 1.3-fold decrease in the absence of a TRE site. As a further control, we also introduced a cJun LZ-only construct in which the 25-residue DBD was deleted. This peptide was unable to initiate DNA binding and, as expected, did not affect bacterial colony formation (P = 0.1, Figure 8B-4 vs. 8B-3). Together, this specifically links the interaction between the cJun bZIP and TRE sites to abrogation of bacterial growth within the TBS system, validating that any subsequent increase in bacterial growth is due to inhibition of this interaction.

[0319] Next, peptides known to bind cJun were introduced into the system to determine if they could have an effect on cJun function—i.e., sequestering cJun bZIP as a nonfunctional heterodimer, thereby preventing DNA binding and rescuing TRE-mDHFR transcription. Here, we used two peptides targeting the cJun LZ domain: cFos LZ and FosW, optimized sequences identified from protein-fragment complementation assays (PCA) that readily bind to cJun with nM affinity in the absence of DNA (Mason et al., 2006; Worral et al., 2011). Despite their known interactions with cJun, both peptides were ineffective in restoring TRE-mDHFR expression and activity, producing no significant increase in colony counts from transcriptionally blocked cells (P>0.05 in both cases, P>0.05). Figure 8B-6 This important finding suggests that although FosW can outcompete cJun dimers to form nonfunctional heterodimers, it cannot release DNA-bound cJun from the TRE site within TRE-mDHFR.

[0320] To address this question, we turned to the work of Olive et al., where acidic cFos (A-Fos) was used to achieve antagonism of cJun, whereby a rationally designed acidic extension was appended to the cFos LZ (Olive et al., 1997). Since FosW was shown to improve binding to cJun LZ relative to the WT cFos LZ sequence in the absence of DNA (Mason et al., 2006), an improved hybrid construct was rationally designed. This was achieved by blending two previously published components to produce A-FosW ( Fig. 9 ). This protein was designed to be used as a template for peptide library design and optimization using TBS screening. Encouragingly, the template peptide was able to successfully antagonize the cJun / TRE DNA interaction, restoring 60% of the colony count relative to TRE-mDHFR alone ( Figure 8B-8 vs. 8B-5). Importantly, all experimental variations above were plasmid matched with appropriate dummy constructs to control for potential differences under antibiotic stress (Table 3). TBS designs are summarized in Fig. 8A middle.

[0321] Table 3: P value table showing the statistical difference between the colony counts of the tested E. coli control strains. Dark red box indicates P ≤ 0.0001, red box indicates P ≤ 0.001, orange indicates P ≤ 0.01, yellow indicates P ≤ 0.05, and white indicates P> 0.05

[0322]

[0323] 1.4 Hinge library design

[0324] The acidic extension design principle is the most successful approach in the literature to target complete bZIP domains of various proteins (Olive et al., 1997; Ahn et al., 1998; Chen et al., 2011). However, the incomplete recovery of colonies using A-FosW indicated that transcription was still partially blocked by cJun binding across the 15 TRE sites. This allowed us to employ TBS to screen a peptide library using A-FosW as a design template to further improve cJun / TRE DNA antagonism. The library design utilized semi-randomized positions within the hinge region spanning the acidic extension and LZ domain ( Fig. 9). It is expected that the optimization of the hinge region will induce significantly improved functional antagonism and high affinity binding, while destroying two cJun LZ dimerizations, and will provide more effective blocking of DBD-DNA interactions by interfering at the region between the two domains. Previous studies have generally attempted to inhibit binding at the DBD or LZ, but here we aim to target these two regions to produce improved antagonists relative to targeting either domain separately. Among the nine semi-randomized hinge positions, four options are included in eight positions (e4, f4, g4, a4, b4, c4, e5, f5 and g5): two hydrophobic (V / L), one acidic (E or D) and one polar (Q or H). The A / E option is included at f5 as the fth position in the LZ region because it is believed that these positions are unlikely to participate in direct target interactions, so these residues are presented to contribute to solubility or higher helical propensity to enhance PPI through entropy pre-organization. Experimental limitations prevent more amino acid diversity from being incorporated at so many positions, however, these selections will allow testing of general amino acid preferences. In all positions, the parent residue of A-Fos was incorporated into the library so that this functionally active benchmark protein was included in the screen. The limitations of the genetic method used to generate the library resulted in different mixtures of residues at different positions. The Leu at d5 in the middle of the segment of semi-randomized positions was kept unchanged because it was thought that the change was unlikely to be favorable or that other coiled-coil structures might be more favorable than the desired parallel dimer. In summary, this generated a peptide library of 131,072 members ( Fig. 9 ).

[0325] 1.5TBS library screening

[0326] During the TBS library screening process, E. coli is transformed with the combined DNA plasmid library so that each cell expresses a given member. The cells are inoculated on M9 selective medium and incubated until colonies expressing TBS-active library members are formed. These colonies are merged and repeated liquid culture passages are performed under selective conditions to allow library members to compete with each other and enrich for the most TBS-active sequences. At each stage of the assay, DNA sequencing is used to monitor the presence of TBS-active sequences in the culture and to inform which residues are selected at each position until a discrete DNA sequence is detected in the culture, called HingeW ( Fig. 9). It was generally found that the residues selected in the winning HingeW peptides were either acidic (D / E) or hydrophobic (V). Six of the nine selected residues deviated from the parent A-FosW sequence, with both V (E to V at e4 and c4, Q to V at f4) and E (L to E at a4, Q to E at e5, A to E at f5) newly selected in three positions. The changes in the proportion of library options at each position during the competition rounds provide information about how preferred a particular residue or residue type may be as the selection progresses ( Fig.10 ). Two residues were selected after the first passage and are therefore considered particularly important for optimization of this interaction: V at f4 (Q in the parental sequence) and E at g4 (unchanged). At position f5, there was little preference for either option at the end of the second passage, with E being selected over A (A in the parental sequence), indicating a smaller effect on target binding. Although the sequence of A-FosW was included in the library, the TBS selection preference of HingeW over the parental sequence was further confirmed by direct competition in liquid culture. In this experiment, the same number of TBS cells containing A-FosW or HingeW were mixed in selective M9 medium and competitively selected. After three passages, only HingeW was observed by DNA sequencing because cells containing A-FosW had been eliminated. This was further supported in TBS colony count experiments, which showed that the colony count of HingeW was increased by 10% relative to A-FosW (P=0.009, Figure 8B-9 vs. 8B-8), rising to 66% of the theoretical maximum colony number observed for TRE-mDHFR alone ( Figure 8B -3).

[0327] 1.6 HingeW binds c-Jun preferentially over A-FosW

[0328] Next, experiments were performed to compare the binding of A-FosW and TBS-optimized HingeW to cJun bZIP. CD spectroscopy was used to measure the overall secondary structure of homodimeric and heterodimeric peptide samples, providing information on overall α-helicity and thermal melting temperatures (Tm). The α-helical content of the HingeW / cJun spectrum was 82% higher ( 0.05 % ) relative to the average of the two component spectra that would be expected to be non-interacting. Fig.11A The same trend, albeit smaller, was observed for the A-FosW / cJun spectrum, where the α-helicity was 39% greater than average ( Fig. 11B). Upon binding, the larger α-helical gain of HingeW / cJun implies a higher affinity interaction. Notably, HingeW alone (in isolation) is 12.9% less helical relative to A-FosW. The AGADIR helical propensity calculator was used to calculate the predicted helicity scores for A-FosW and HingeW, which were 14.5 and 13.2, respectively ( et al. 1994). The observed differences in the helicity of the heterodimeric peptides could be explained in part by A-FosW being inherently more helical, but the observed effects being larger than this prediction could likely be explained by the homodimer preference of A-FosW relative to HingeW.

[0329] After the signal loss at 222 nm, thermal denaturation analysis of HingeW / cJun showed that the Tm of the HingeW / cJun heterodimer was 71.2 °C, which indicates that the Tm of the denaturation spectra of the two components was significantly increased ( Fig. 11C For A-FosW / cJun, the observed Tm was 69.9°C ( Fig.11D ). Although this represents a negligible 1.3°C increase in the heterodimer Tm, the key point is that relative to the component peptide denaturation spectra, the ΔTm of HingeW / cJun is much greater than that of A-FosW / cJun. The low thermal stability of the HingeW homodimer results in no observable lower baseline before the transition, making it impossible to determine the Tm of this component, and therefore the average value. However, compared to 27.5°C for A-FosW / cJun, the ΔTm can be estimated to be around 40°C. Therefore, the TBS screen results in an optimized reduction in homodimerization more than the increase in heterodimerization with the target. This ensures that more of the antagonist is available as a free monomer in solution and is therefore in a target-dimerisation competent state. Another difference between the two denaturation spectra is the presence of a dual transition for the A-FosW / cJun heterodimer, with a smaller initial transition occurring at around 30°C. Jain et al. have previously reported a similar dual transition in the acidic extension antagonist / bZIP denaturation profile and suggested that the lower temperature transition occurs due to the attrition of the N-terminal acidic extension / DBD interaction, with the higher temperature transition corresponding to the dissociation of the LZ region (Jain P et al., 2017). Crucially, the two new antagonists have significantly higher Tm values ​​for the target heterodimer than FosW (Tm = 54 °C, Fig.12 This suggests a clear benefit from including an acidic stretch that is not present in FosW. Importantly, due to the sequence differences between cJun and cFos ( Fig. 9), optimization of cJun binding means that HingeW was shown not to interact with the cFos bZIP domain ( Fig.13 ).

[0330] 1.7 HingeW outperforms A-FosW in c-Jun binding

[0331] Direct competition between HingeW and A-FosW for cJun binding was observed using a CD dimer exchange experiment, in which a solution containing one antagonist / cJun mixture was combined with another antagonist to observe potential changes in α-helicity as an indicator of changes in the dimerization partner of cJun. In this case, when HingeW was mixed with preformed A-FosW / cJun heterodimers, a 17% increase in helicity relative to the average (as measured at 222 nm) was observed, indicating a change in binding ( Fig.11E ). The peak at 190 nm also has a clear increase relative to the average of the two-component peptide spectrum. Reversing the experiment and mixing A-FosW with the preformed HingeW / cJun heterodimer produced a measured spectrum that overlapped with the average of the components, indicating that no dimer exchange occurred ( Fig.11F ). Combined with the TBS growth competition data, the dimer exchange experiments strongly suggest that HingeW preferentially binds to cJun relative to A-FosW during competition.

[0332] 1.8 Isothermal titration calorimetry demonstrates improved binding affinity of HingeW

[0333] The binding interactions of cJun with HingeW and A-FosW were further investigated by ITC to provide information on the thermodynamic parameters. The data generated from the injection of HingeW into cJun ( Fig.14A ) was fitted to a single-site binding model (N = 1.05 ± 0.05), with a KD of 14.4 ± 3.7 nM and a ΔH of -85.4 ± 4.5 KJ mol-1 (tΔS = -39.2 ± 4.5 KJ mol-1). A-FosW ( Fig. 14B ) were fitted to a single-site model (N = 1.04 ± 0.08), with a KD of 88.3 ± 17.6 nM and a ΔH of -152.6 ± 4.1 KJ mol-1 (TΔS = -112.6 ± 4.1 KJ mol-1). This determined the predicted 1:1 binding stoichiometry for both interactions, while demonstrating a 6-fold increase in binding affinity after TBS optimization of A-FosW with HingeW. Both interactions are driven by negative entropy contributions, with the latter being less unfavorable for the HingeW interaction.

[0334] 1.9 HingeW effectively antagonizes c-Jun / TREDNA interaction

[0335] Binding of cJun to TRE DNA can be observed by monitoring the DNA absorption peak centered at about 281 nm in the CD spectrum (John M et al., 1996). Individual peptides (cJun, HingeW, or A-FosW) do not absorb at this wavelength, meaning that all changes in the spectrum in this region correspond to changes in DNA conformation. Since cJun binds to its target TRE site and alters the DNA structure, the addition of cJun (20 μM) to TRE DNA (5 μM) reduced this DNA peak by 55% ( Fig.15A ). Subsequent titration of HingeW into this bound cJun / TRE DNA mixture reversed the peak shift, with the peak increasing as DNA was released. This occurred in a dose-dependent manner until the signal overlapped with the free DNA spectrum at 50 and 100 μM HingeW concentrations, indicating complete antagonism of the cJun / TRE interaction. Plotting the relative peak shift and fitting it to the Hill equation (OriginPro) yielded an IC50 of 13.4 ± 0.6 μM, which can be compared to equivalent data for A-FosW antagonism, which yielded an IC50 of 16.0 ± 0.4 μM ( Fig. 15B This showed a significant improvement over FosW lacking the acidic extension in both cases and exhibited an IC50 of 119.8 ± 1.1 μM ( Fig.16 In control experiments, it was shown that neither HingeW nor A-FosW interacted with DNA ( Fig.17 ).

[0336] To provide additional evidence of functional antagonism, an electrophoretic mobility shift assay (EMSA) was employed. First, cJun bZIP (20 μM) was mixed with TRE DNA construct (2 μM), resulting in a significant reduction in free DNA band intensity relative to DNA alone ( FIG. 15C ). Since the total charge of the complex prevents entry into the gel, no bound cJun / TRE DNA bands were observed. Therefore, antagonism is best observed by monitoring the intensity of the free DNA band. After HingeW was added to cJun / TRE DNA, a concentration-dependent increase in the intensity of the free DNA band was observed ( FIG. 15D ). The same trend was observed with increasing concentrations of A-FosW and cJun / TRE DNA ( FIG. 15E ). In close agreement with the CD DNA peak analysis, the data can be fitted to the Hill equation (OriginPro) to determine that the IC50 value for HingeW is 9.6±0.8 μM and the IC50 value for A-FosW is 12.1±1.9 μM. In good agreement with the CD DNA peak analysis, the data were fitted to the Hill equation (OriginPro) to determine that the IC50 value for HingeW was 9.6 ± 0.8 μM and the IC50 value for A-FosW was 12.1 ± 1.9 μM ( Fig.15F ).

[0337] Thermodynamic parameters for the interaction between c-Jun and the rationally designed A-FosW template or TBS library-derived HingeW are summarized in Table 4 below:

[0338] Table 4: Thermodynamic parameters for the interaction between c-Jun and rationally designed A-FosW template or TBS library derived HingeW. Errors are shown as one standard deviation.

[0339]

[0340] 1.10 Conclusion

[0341] There are many suitable screening platforms to obtain high affinity PPIs, but none of them guarantees that target binding will result in the desired loss of function of the target protein. Using cJun / TRE as an example, we have developed such a transcription blocking survival assay that can be used as a general method for deriving peptides capable of eliminating TF activity. We have transformed the "molecular dial" into a bacterial system in which cJun / TRE DNA interactions are negatively correlated with cell proliferation. By introducing cJun / TRE antagonists into this system, cell growth becomes a direct readout of the ability of the antagonist to functionally block many cJun / TRE interactions, raising the molecular dial. Next, the most effective rationally designed acidic antagonists were used as parental sequences to design a semi-randomized library that was successfully screened in the TBS platform to generate the in vitro validated assay hit HingeW.

[0342] Establishing TBS system needs to produce mutated DHFR gene (TRE-mDHFR), and the mutated DHFR gene keeps its enzymatic activity after 15 TRE sites are introduced into its DNA sequence, resulting in 13 amino acid replacements. When TF combines with TRE sites on TRE-mDHFR plasmid DNA, this allows transcriptional blocking induced by cJun. Both TF DBD and TRE sites in mDHFR gene are absolutely necessary for TRE-mDHFR activity loss, which determines the specificity of TBS system. The phenotype of bacterial growth rate is directly related to the genotype of antagonist sequence expressed due to the containment of the system in single cell. The phenotype of bacterial growth rate is directly related to the genotype of antagonist sequence expressed due to the containment of the system within single cell. Bacterial cells are ideal for this process due to their fast growth rate, durability, ease of use and low cost. Crucially, they also allow direct measurement of cJun interacting with TRE sites in the absence of any relevant eukaryotic TF that can interfere with the determination.

[0343] TBS facilitates high-throughput genotype-to-phenotype screening and competition of peptide libraries to separate those that cause functional loss of cJun DNA binding activity from those that bind but have little or no effect on target activity (or those that do not bind at all). This distinction is important because it means that antagonists must not only bind to the target free in solution, but must also be able to meet the more demanding task of releasing TF from DNA (which is known to be more stable) (Seldeen et al., 2011). Finally, all of the above is performed within the complex environment of the cytoplasm, considering the removal of toxic, non-specific, insoluble or protease-sensitive molecules in the initial screening stage, rather than determining this later in the hit validation or clinical trial stage. These factors are particularly important for longer peptides because of the need to bind to the large and shallow cJun bZIP surface, which often lacks these important qualities. TBS improves related protein fragment complementation assays as well as in vitro screening platforms such as phage display or ribosome display by completely removing any requirement for hydrophobic / aromatic tags or bulky protein fusions that can interfere with relevant assay interactions and lead to erroneous readouts.

[0344] A core advantage of TBS is that hits need to be determined to prevent TF binding to their consensus DNA sequences, as exemplified by the combinatorial design of A-FosW, a hybrid containing domains from both A-Fos (Olive et al., 1997) and FosW PCA hits (Mason et al., 2006). In A-FosW, LZ targets antagonists to cJun bZIPs with high affinity and selectivity, where the added acidic extension assists in functionally antagonizing cJun / TRE DNA interactions by blocking the cJun DBD. The LZ domains of bZIP proteins tend to show more sequence diversity than the DBD, which can be used for therapeutic targeting of specific AP-1 family members, providing better control and potentially fewer side effects (Eferl et al., 2003). Although it is unclear whether A-FosW interacts with cJun by forming a single continuous LZ as designed, it is expected that the increase in the cJun hinge region surrounding the combination will propagate the helicity of the increase, and therefore the affinity in either direction is increased. In addition, focusing on the hinge region is supported in the initial work of Olive et al., wherein the point mutation in this region of A-Fos (N26L at the a4 position of A-FosW) produces significantly improved cJun binding affinity and subsequent cJun / TRE antagonism (Olive M et al., 1997). The optimization of the acidic extension portion carried out by rational design is hindered by the lack of design rule guidance, and the situation of the LZ domain is just like this, and it has known structure and prediction tools to produce high affinity interactions (Boysen RI et al., 2002; Kaplan JB et al., 2014). In addition, previously, the combination in this region of cJun was not optimized using a library-based method. Using A-FosW as a design template and including library options in the hinge region was the clear next step, which led to the TBS selection of HingeW, with an affinity of 14nM for the target cJun protein (a 6-fold improvement over A-FosW). HingeW contains one more acidic residue than A-FosW, which supports the approach of Olive et al.: containing a dominant negative charge throughout the N-terminal domain to interact favorably with the positive charge within the cJun DBD. However, the precise selection pattern is more subtle than simply generating a set of negatively charged residues. The properties of HingeW indicate additional benefits of the TBS library screening approach, in which the directed evolution of antagonists leads to improvements by reducing homodimerization. TBS has provided considerable utility in exploring new sequence space by generating protein sequences that would not have been predicted without the use of the library screening approach.

[0345] TBS opens new capabilities in semi-rational PPI design, where both affinity and activity are co-selected. This provides great potential for extending the TBS approach to both new libraries and targets, where previous work may have produced potential antagonists that were later found to lack functional activity. In principle, the approach can be fully extended to any DNA binding protein that recognizes a discrete consensus sequence, or even to any DBD-attached dimer system. It can be assumed that the approach is generalizable because any DNA consensus sequence can be incorporated into the DHFR DNA sequence and can be transcriptionally blocked by co-expression of the relevant TF. This will require repetition of the DHFR design process and subsequent testing and optimization of each system, however, the central principles have been demonstrated here to be effective. It also potentially allows screening of exogenous molecules to allow simultaneous analysis of both cell permeability and functional activity inhibitors. In addition, libraries with different design principles and expansion options have considerable additional prospects in generating peptide hits for a wide range of targets involving pathogenic TFs. Using standard techniques and readily available reagents, 10 6 Up to 10 7 Library sizes of 1000 Å are possible, which may allow for the exploitation of a wider peptide diversity and further optimization. Further TBS screening of a range of TF targets will generate both probes and non-genetic tools for disease pathways, but a new generation of optimized functional antagonists and clinical leads also has considerable potential.

[0346] Example 2 - Optimization of functional c-Jun antagonists

[0347] This example shows the optimization of the hits from the peptide library screening of Example 1, which were designed to target the complete cJun bZIP domain, attempting to simultaneously block both cJun dimerization and DNA binding. The TBS screening of the peptide library of 130,000 members produced the HingeW sequence (HW1). Relative to cJun inhibitors of only DBD or only LZ, HingeW was developed to be able to bind to the complete cJun bZIP domain for more effective functional antagonism of TRE binding. The properties of the wide, shallow helical binding surface support the use of longer peptides, such as Hinge. However, it is not clear whether the full-length sequence is required to achieve functional antagonism. HW1 is recombinantly produced and biopharmacologically characterized as a capped (MAS at the N-terminus and GAP at the C-terminus) with a length of 69 amino acids and a 6×His-tagged protein construct at the C-terminus, with a significant negative charge throughout. The peptides were optimized to improve their drug-like characteristics.

[0348] 2.1 Methods

[0349] Peptide synthesis and purification: All peptides were synthesized on a 0.1 mmol scale using a Liberty Blue microwave peptide synthesizer (CEM) on ChemMatrix Rink amidine resin using a standard Fmoc solid phase method. Coupling was performed using 5× amino acids, 4.5× PyBOP, and 10× diisopropylethylamine in dimethylformamide (DMF, 5 mL). Deprotection was performed using 20% ​​piperidine in DMF. The peptide was capped at the N-terminus by a final reaction with 3× acetic anhydride, 4.5× diisopropylethylamine in DMF for 5 minutes at 90°C. For lactamized peptides, the relevant K and D positions were orthogonally protected by using Lys (Mtt) and Asp (O-2-PhiPr). The side chains of these residues were selectively deprotected by washing the resin with dichloromethane (DCM) × 3, 2% trifluoroacetic acid (TFA) in DCM × 10, DCM 3×, and then DMF 3×. The newly deprotected side chain was coupled in PyBOP (1 mL), diisopropylethylamine (1 mL) and DMF (3 mL) at 60°C for 5 hours. The resin was dried and the same reagents were added for a second reaction at 60°C for 16 hours. The peptide was cleaved from the resin and the side chain protecting groups were removed by incubation in a cleavage mixture (95% TFA, 2.5% triisopropylsilane, 2.5% H2O, 10 mL) at room temperature for 4 hours. The resin was removed by filtration, and the cleaved peptide was precipitated in ether at -80°C and centrifuged. The precipitate was washed an additional four times with ether and then dried at room temperature overnight. The peptide was resuspended in 3:1 water:acetonitrile and then purified using a Jupiter Proteo column (4-μm particle size, Purification was performed by RP-HPLC using a water:acetonitrile gradient (0.1% TFA) and electrospray ionization mass spectrometry to verify peptide quality and purity (>95%).

[0350] Circular Dichroism (CD): CD measurements were performed using Applied Photophysics Chiral Scanning with 200 μL samples in a CD cell with a 1 mm optical path length. Protein / DNA samples were suspended in 150 mM potassium phosphate, 150 mM potassium fluoride, and 5 mM TCEP at pH 7.4 and equilibrated for 30 minutes prior to measurement. For the full spectrum, three scans between 190 and 260 nm (265 to 320 nm for DNA binding experiments) were collected with a bandwidth of 1 nm, and data were acquired at a rate of 0.5 sec-1. These scans were averaged and converted to molar residual ellipticity (MRE). Thermal denaturation experiments were performed by measuring the ellipticity at 222 nm in a gradient of 1 to 90 °C with 1 °C increments. Post-melting scans at 20 °C determined that the transitions were reversible because they overlapped within 10% of the scans before melting. The resulting thermal denaturation curves were converted to MREs and fitted to a two-state model derived by modifying the Gibbs-Helmholtz equation to determine the melting temperature (Tm) (Mason et al., 2007).

[0351] Serum stability: Peptide stock solutions (600 μM) were prepared in water and 50 μL was added to 950 μL human serum (Merck) and then incubated at 37°C. 100 μL aliquots were removed at designated time points and added to 300 μL 3:1 acetonitrile: water and centrifuged (18000×g, 15 min). The supernatant was analyzed by LC-MS and quantified using the sum of the two maximum charge state intensities (1: 9+, 10+; 23, 24: 3+, 4+).

[0352] Isothermal titration calorimetry (ITC): Peptides were studied by ITC using PEAQ-ITC (Malvern Instruments) using an ITC buffer of pH 7.4 consisting of 10 mM potassium phosphate, 150 mM potassium fluoride and 5 mM TCEP. 2 μL of 25 to 200 μM antagonist peptide injections were injected into cells containing 2.5 to 20 μM cJun. The thermal changes after addition were recorded and analyzed using software. Control experiments involved injecting antagonist peptide samples into cells containing ITC buffer alone to determine the subtracted heat of dilution. The resulting binding data were fitted to a one-site binding model to extract the enthalpy change (ΔH) and equilibrium binding constant (KD) of binding, from which the free energy change (ΔG) of binding and the entropy change (ΔS) of binding were calculated (Wiseman et al., 1989). Thermodynamic parameters are expressed as the average of two independent experiments, with the error expressed as one standard deviation.

[0353] 2.2 Acidic / N-terminal truncation

[0354] A summary of the various peptides used and described in this section is provided in Table 5 below:

[0355] Table 5: Summary of tested peptides

[0356]

[0357] The precise nature of the interaction between the c-Jun DBD and the rationally designed acidic domain of 1 is unknown. Therefore, the acidic domain was the initial focus for optimization. 1 was iteratively truncated (2 to 6) to study the effect on c-Jun binding and c-Jun / TRE DNA antagonism. Peptide helicity was determined by quantifying the CD signal at 222 nm for samples of peptide only. Thermal denaturation experiments were then used to determine the T of the peptide-c-Jun heterodimer. m , which serves as an approximate measure of target engagement. CD is also used to study the ability of peptides to antagonize the functional activity of c-Jun / TRE DNA interactions. The TRE-DNA construct used produces a positive CD peak at about 281 nm (no c-Jun absorption at this wavelength, allowing direct measurement of DNA upon binding), which decreases in intensity upon c-Jun binding. This provides a clear and direct measure of the proportion of DNA binding. As increasing concentrations of antagonist peptide are added to the sample, the peak shifts back to overlap with free TRE-DNA. This allows the calculation of IC by fitting the titration data to the Hill equation 50 Since higher concentrations were required in these experiments (in order to detect a signal in CD), the IC 50 The values ​​are correspondingly higher, since cJun under the experimental conditions was 20 μM and the lowest value to which the IC50 could be reduced was 10 μM. Therefore, these values ​​should be considered in context, not compared to values ​​generated by different methods, but rather used here for comparison between the tested antagonists. All experiments used the same 60 amino acid c-Jun bZIP construct, regardless of the antagonist peptide length. With these experiments, both target binding and subsequent target antagonism were rapidly characterized in vitro.

[0358] The thermal denaturation (T m ), functional activity (IC 50 A summary of the CD (μM)), helicity (fH (%)) results is provided in Table 6 below:

[0359] Table 6: Summary of thermal denaturation, functional activity and helicity results

[0360] Peptide# <![CDATA[T m (℃)]]> <![CDATA[IC 50 CD(μM)]]> fH(%) Truncation 1 71.2±1.4 13.4±0.6 27.2 - 2 68.5±1.1 16.6±0.5 32.8 NΔ10 CΔ3 3 67.9±0.9 33.7±2.8 38.3 NΔ1 7CΔ3 4 64.1±1.5 45.4±3.6 45.5 NΔ20 CΔ3 5 62.8±1.0 78.2±4.1 46.7 NΔ24 CΔ3 6 55.1±1.1 129.8±13.0 38.0 NΔ28 7 64.3±1.3 83.9±6.2 45.6 NΔ24 CΔ3 8 67.2±0.8 73.5±5.2 54.2 NΔ24 CΔ3 9 62.1±1.4 94.6±7.4 43.0 NΔ24 CΔ3 10 68.3±0.9 69±4.1 46.8 NΔ24 CΔ3 11 57.1±0.9 82.1±6.0 37.3 NΔ20 CΔ7 12 56.5±1.6 115.0±13.4 38.7 NΔ19 CΔ7 13 58.5±1.0 92.5±3.4 40.1 NΔ19 CΔ7 14 57.5±1.1 100.4±3.9 36.9 NΔ20 CΔ7 15 59.4±1.0 81.1±5.7 39.2 NΔ20 CΔ7 16 54.9±1.2 113.6±10.8 37.2 NΔ20 CΔ7 17 64.0±0.8 74.9±4.1 42.6 NΔ20 CΔ7 18 55.5±1.7 98.9±5.1 37.0 NΔ20 CΔ7 19 60.9±3.6 94.4±4.5 38.7 NΔ20 CΔ7 20 56.2±1.3 120.8±17.3 36.0 NΔ20 CΔ7 21 58.9±1.0 94.1±6.0 38.5 NΔ20 CΔ7 22 55.6±1.2 100.8±3.7 35.0 NΔ20 CΔ7 23 65.0±1.4 52.7±2.0 43.4 NΔ20 CΔ7 24 63.2±1.3 44.9±2.1 47.1 NΔ20 CΔ7 25 44.8±1.2 1212.9±118.4 32.8 NΔ20 CΔ10 26 ND 1559.5±143.9 30.1 NΔ20 CΔ10 27 52.5±1.4 118.5±10.9 35.0 NΔ20 CΔ10 28 53.8±5.3 725±62.6 31.2 NΔ20 CΔ9 29 57.2±0.4 140±14.3 36.4 NΔ20 CΔ9

[0361] All N-terminal truncations in the series (2 to 6) reduce peptide / target binding and antagonistic potency, indicating that the full length of the acidic extension contributes to the antagonism of c-Jun / TRE interactions (Figure 18). However, each truncation in the series has an increasing impact on the antagonism of each removed residue. Inspection of truncations from 1 to 2, from 2 to 3, and from 3 to 5 (representing three complete heptapeptide N-terminal deletions) revealed that antagonism was reduced by 1.2 times, 2 times, and 2.3 times, respectively. As expected, as each subsequent heptapeptide is deleted, the percentage of loss increases and therefore becomes more important to antagonism. In addition, the final N-terminal truncation studied (from 5 to 6) reduces antagonism by 1.7 times, although only four residues are removed. Peptide 6 (NΔ28) represents only the LZ portion of the HingeW molecule. In order to test the possibility that a single acidic domain can antagonize c-Jun, this single portion was also tested and displayed as non-binding (data not shown). This suggests that the acidic extension and LZ domain of HingeW act synergistically to bind and antagonize c-Jun.

[0362] Truncations of the N-terminus also resulted in a continuous increase in fractional helicity (fH), from about 27% in 1 to about 47% in 5, indicating that the deleted region has a lower helicity relative to the LZ region. The LZ domain of 1 is almost unchanged relative to its parental sequence, FosW, which is known to homodimerize (Mason et al., 2006). The negative charges of the acidic extensions produce electrostatic repulsion and thus reduce the propensity for homodimerization, wherein their removal increases the helicity induced by homodimerization. However, further truncation from 5 to 6 reverses this trend, reducing fH to about 38.0%, while removing one acidic and three hydrophobic residues to leave only the LZ domain. Although electrostatic repulsion is hardly reduced further, this region may contribute to homodimerization through direct binding or helical induction.

[0363] Overall, removal of the acidic extension domains (1 to 6) reduced cJun / TRE DNA antagonism by 9.7-fold. 50 IC values ​​similar to (130 μM) 50 A highly significant reduction in peptide activity was observed during TBS screening of peptides with values ​​of 6, suggesting that 6 may not be able to completely outcompete cJun / TRE DNA binding. This further supports the design rationale for the acidic extension and suggests that 5 (IC50 = 78 uM, 5.8× lower antagonism than 1 and 1.7× greater than 6) can be considered the largest feasible truncation from the N-terminus onward.

[0364] 2.3 Lactamization of N-terminal truncation

[0365] Peptide 5 was next optimized by incorporating an i→i+4 (K to D) lactam bridge. The lactam bridge can be incorporated using orthogonal protecting groups (Lys(Mtt) and Asp(O-2-PhiPr)) that can be selectively deprotected (2% trifluoroacetic acid in DCM) and reacted using typical solid phase chemistry while the peptide remains attached to the resin. Mass spectrometry (MS) can be used to confirm the success of the reaction by observing the reduced mass due to the loss of water molecules compared to the linear unreacted peptide. In this example, lactams were introduced only at the solvent-exposed b to f or f to c heptapeptide positions to prevent disruption of the helical binding surface. Point mutations were required to the sequence to incorporate the bridging K and D residues, with both the linear (7,9) and cyclized (8,10) forms of each sequence produced by batch synthesis.

[0366] Cyclized peptides 8 and 10 increased antagonism by 1.8-fold and 1.9-fold, respectively, relative to their linear counterparts 5. Side chain lactamization results in increased helicity, which translates into higher affinity binding. Notably, in these peptides, the T values ​​of about 67°C and about 68°C were significantly higher than those of the linear counterparts 5. m Values ​​indicate binding that does not result in a correspondingly low IC 50 As expected, T m The IC of each peptide 50 Negative correlation, however there is a certain level of variability in the trend ( Fig.19 ). For example, peptides 2 and 10 have similar T m values, but 2 was 4× more potent in antagonizing the cJun / TRE interaction. 10 was truncated by an additional 14 N-terminal residues compared to 2. This supports the importance of the rational design principles used for HingeW, whereby inhibition of both domains of the cJun bZIP resulted in the most potent antagonism, as most of the acidic stretches in peptides 5 and 7 to 10 had been removed, and all of the acidic stretch in peptide 6 had been removed. This resulted in peptides that could be optimized to bind tightly to the cJun LZ, but they were limited in their ability to functionally antagonize cJun by also blocking the DBD.

[0367] The truncation from 4 to 5 removed the negatively charged block (EAEE) and resulted in a 1.7× decrease in antagonism. This suggests that this region is important for interacting with the positively charged cJun DBD surface and inducing helicity and potentially stabilizing the dipole of the molecule (Pace et al., 1998; Sali et al., 1988). This correlates with work on the interaction of cJun DBD with TRE DNA, which showed specific residues that interact directly with DNA. The central two residues of this added block (EEE) AEE-moves from 10 to 11) occur at positions corresponding to interactions with DNA on cJun, i.e., these residues contribute to a direct block between cJun and DNA. Thus, NΔ20 truncation can be viewed as an optimal balance between size reduction and retention of functional activity.

[0368] 2.4 C-terminal truncation

[0369] Therefore, peptide 11 was the next step in optimization, which was truncated with NΔ20 while also being truncated at the C-terminus. Removal of the four C-terminal residues from 4 to 11 reduced antagonism by 1.8×, but further truncation at the C-terminus to produce 25 greatly reduced antagonism by 14.8× compared to 11, and by 26.7× compared to 4. Attempts to optimize 25 by lactamization to produce 27 and 29 were effective in that they significantly increased antagonism, however they still produced 8.8× and 10.4× reductions in antagonism relative to 1. Although these lactamizations produced much greater effects on the peptides, they were still considered to be effectively invalid for further study.

[0370] 2.5 11 Optimization

[0371] Peptide 11 was considered as a scaffold for further optimization, having almost half the number of residues compared to 1 while retaining a high level of functional activity. K to D lactam bridges at positions i to i+4 were systematically incorporated at different sites to investigate which regions were most susceptible to helical constraints and which regions yielded improvements in affinity and inhibition. Again, both linear and cyclized peptides were generated due to point mutations to accommodate bridging K and D residues. Heterodimer ΔT from lactamization m The range of ΔT was about 2°C for 14 / 15 to about 9°C for 22 / 23. It can also be used to compare with the original parent sequence, the heterodimer ΔT of the original parent sequence is m The range was about 1°C for 11 / 13 to about 8°C for 11 / 23. However, C-Jun / TRE antagonism was the most important measure in this study, and only 23 produced an IC 50 23 showed a significant improvement, showing 1.6× lower than 11 (P=0.003). By using a lactam, 23 restored the reduction in antagonism caused by truncation of the four C-terminal residues of 4.

[0372] Information about the suitability of each site for lactamization can be gleaned from this data, as the fractional helicity of the peptides ranged from about 1% for 12 / 13 to about 8% for 22 / 23. There was a correlation between the increase in peptide helicity induced by lactamization at a particular site and the observed increase in cJun / TRE antagonism.

[0373] Although lactamization within 17 did not result in a significant increase in antagonism (P = 0.24), it did produce an approximately 5% increase in peptide helicity and cJun heterodimer T m The result was an increase of about 9°C relative to its linear form 16. Due to the distance between this site and the lactamization site of 23, a doubly lactamylated peptide 24 was generated. Compared to the best monolactamylated peptide, doubly lactamylated peptides produced peptides that were about 4% more helical, heterodimeric, and m No significant changes, but IC 50 The value was significantly decreased (P=0.02).

[0374] The most potent peptides selected from this work were studied by ITC to quantify the thermodynamic parameters of their interaction with the target cJun ( Fig. 20 , Table 7). The two monolactam peptides that were most effective in the CD experiments and the dilactams using these two peptides were tested and compared to the parent sequence. 1 / cJun has been previously studied by ITC, but at higher temperatures, resulting in K values ​​lower than those reported here. D All studied interactions are dominated by the enthalpy component with a smaller unfavorable entropic contribution. This unfavorable entropic component is largest for the 24 / cJun interaction and smallest for the 17 / cJun interaction.

[0375] Table 7: ITC derived thermodynamic parameters of c-Jun-peptide interactions. Thermodynamic parameters are presented as the mean of two independent experiments, with the error represented as one SD.

[0376]

[0377] The serum stability of 1, 23, and 24 was also tested to illustrate the effects of truncation and lactamization ( Fig.21 ). At 24 hours, 1 was degraded by 67%, 23 by 21% and 24 by 7%. Only 1 showed the exponential decay required to fit to the exponential decay model, which indicated a half-life of 18.9 hours. After 96 hours, no peak corresponding to 1 was observed in MS. At this endpoint, the peak intensity of 23 was still 17% of its starting value and 24 was 35%. This clearly illustrates the increased stability provided by the non-natural lactam bridge, and the effect is cumulative, as 24 is more stable than 23 (P=0.038).

[0378] 2.5 Conclusion

[0379] Through a systematic study of truncation and helix-induced lactamization, a series of rationally designed peptides were synthesized to study and optimize HingeW (1). It was demonstrated that 1 could not be obtained by SPPS using standard techniques (i.e., without native chemical ligation), and 2 and 3 were produced only in significantly low yields. The remaining smaller peptides were all produced by SPPS in similar and high yields. The increase in production efficiency obtained by moving from recombinant expression to SPPS cannot be underestimated. The process of iterative truncation and characterization elucidates the effectiveness of different parts of the parent sequence and allows careful consideration of how much peptide to truncate to obtain the minimum effective sequence. In this example, an important consideration is whether a peptide that binds to the target c-Jun can outcompete dimer-Jun that binds to the TRE. This interaction has been variously determined to have a K of approximately 100 to 200 nM. D , so maintaining an interaction stronger than this is considered an important benchmark (Seldeen et al., 2011). Comparing the CD antagonism data of 1 with 6 ( Fig.18B ) illustrates this important consideration, as 1 was able to restore the TRE DNA peak to its unbound intensity, indicating that no DNA was bound to c-Jun at high peptide concentrations. However, while 6 inhibited the interaction, it can be seen that the line does not trend toward 1, and some c-Jun / TRE DNA complexes will remain regardless of the amount of 6 present in the sample. The balance between this loss of potency and the gain in drug-like characteristics and synthetic potency is difficult to quantify, but the data suggest that the truncation from 1 to 4 removes 20 residues from the N-terminus. Truncation from 4 to 11 at the C-terminus is also supported, as more truncation weakens the potency of the peptide to a point where even lactamization cannot restore binding to the point where the peptide can overcome the c-Jun / TRE DNA interaction.

[0380] The acceptable degree of truncation at the N-terminus appears to go beyond considerations of binding affinity, as this acidic domain is critical for blocking the c-Jun DBD. Peptides 5 to 10 are no longer able to effectively prevent DNA from binding to the c-Jun DBD, i.e., c-Jun can still bind to the TRE site as a monomer when these antagonist peptides are bound to their LZ domains. However, effective antagonism may not require full-length binding to the c-Jun DBD. Specific contacts between specific c-Jun DBD amino acid side chains and TRE DNA bases are known, so it can be assumed that antagonists that bind to any of these c-Jun residues will significantly reduce c-Jun / TRE binding, and therefore may not require binding to the complete DBD to maintain high levels of inhibition (Glover et al., 1995; Seldeen et al., 2011). Therefore, peptide 4 appears to be the most acceptable truncation, as it extends to the point at the N-terminus that can directly block the interaction of the c-Jun DBD with DNA, and it is critical to present a blockade of negatively charged residues in this region to attract the DBD and repel DNA. Due to the addition of the EAEE residue, 4 has slightly reduced homodimerization and better antagonism compared to 5.

[0381] Almost half the length of 1 has been removed to produce 24, where a high level of potency is retained. Due to the nature of the α-helical coiled-coil structure and hydrogen-bonding network, residues that are not involved in binding to the peptide's dimer partner can still affect binding by inducing helicity. In addition, the helicity of the peptides studied here must be considered in their various dimerization equilibria (e.g., between homodimers, monomers, and heterodimers), where an increase in any one dimerization event tends to result in an increase in helicity. Unless the removed residue disrupts the structure (e.g., if it contains proline or glycine) or repels the dimer binding partner (e.g., electrostatic repulsion), reducing the length of the α-helix will tend to reduce its helicity.

[0382] A 20% increase in peptide helicity from 1 to 24 resulted in improved peptide serum stability. In particular, the N-terminal regions of full-length 1 were shown to be non-helical and did not improve target antagonism, so their removal improved stability without a significant effect on peptide potency. Cyclization increased peptide helicity, which reduced protease recognition and increased peptide serum stability. Addition of a second lactam in 24 did further improve this stability, although the increase in stability was smaller than the addition of the first lactam. Peptide degradation of the lactamylated peptide could not be fit to an exponential decay function because it occurred too slowly.

[0383] Particular lactam flanking residues at any given position may be better suited than other residues to accommodate a lactam and adopt a helical structure. How a peptide folds to adopt a helical structure may also affect the effects of lactams, because, for example, if the helical fold is propagated from one end of the peptide to the other, the effects of lactams will likely vary depending on their proximity to this folding site.

[0384] The binding thermodynamic parameters observed by ITC show slightly unexpected results in terms of the entropy component. It is generally believed that the introduction of lactam bridges improves binding affinity by pre-organizing the peptide molecules into their helical structures, which can bind to the target with an entropy penalty. All peptides studied by ITC have an unfavorable entropy component, but 17 has a significantly lower contribution from this component. In this case, it is indeed shown that the entropy penalty of binding is reduced by pre-organizing the peptide into a helical fold complementary to the cJun binding surface. However, for 23 and particularly 24, there is a large unfavorable contribution from the entropy component. This shows that the improvement of target binding affinity from side chain cyclization can also occur due to improved enthalpy interactions.

[0385] Example 3 - Double Alkylation of HingeW

[0386] To identify additional peptide HingeW variants that could be cyclized using dialkylation rather than lactamization, the c-Jun antagonist sequences were screened using the TBS library screen described in Example 1. This screening identified the sequences shown in Table 8 below.

[0387] Table 8 - HingeW variants suitable for bis-alkylation with metaDBMB.

[0388]

[0389] Of the five sequences listed in Table 8, OW and metaDBMBW were cyclized using dialkylation with mDBMB and the functional activities of the linear and cyclized forms were tested in the CD assay and the results and CD curves were compared in Table 8. Fig.23 Shown in. Fig.23 It was shown that the circularized metaDBMBW and OW improved c-Jun target binding compared to their linear counterparts and this is reflected in the lower IC50s of the circularized variants as shown in Table 9.

[0390] Table 9: Functional activities of listed peptide variants (IC 50 CD). Error is standard deviation (SD).

[0391]

[0392] References

[0393] Many publications are cited above to more fully describe and disclose the present invention and the prior art in the field to which the present invention belongs. The complete citations of these references are provided below. The entire contents of each of these references are incorporated herein.

[0394] Ahn et al., A dominant-negative inhibitor of CREB reveals that it is a general mediator of stimulus-dependent transcription of c-fos. Mol Cell Biol 18, 967-977 (1998).

[0395] Alani et al., The transactivating domain of the c-Jun proto-oncoprotein is required for cotransformation of rat embryo cells. Mol CellBiol 11, 6286-6295 (1991).

[0396] de Araujo, et al., Comparative α-helicity of cyclic pentapeptides inwater. Angew Chem Int Ed Engl, .53(27): p.6965-9. (2014)

[0397] Azzarito, V.et al., Inhibition of α-helix-mediated protein-protein interactions using designed molecules. Nature chemistry, 5(3), 161-173. (2013)

[0398] Baxter et al., Library construction, selection and modification strategies to generate therapeutic peptide-based modulators of protein-protein interactions. FutureMed Chem 6, 2073-2092 (2014).

[0399] Baxter et al.,Exploiting Overlapping Advantages of ln Vitro and InCellulo Selection Systems to Isolate a Novel High-Affinity cJunAntagonist.ACS Chem Biol 12,2579-2588(2017).

[0400] Boysen et al.,Role of interfacial hyd rophobic residues in thestabilization of the leucine zipper structuresof the transcription factors c-Fos and c-Jun.J Biol Chem 277,23-31(2002).

[0401] Brennan,et al.,Selective antagonism of cJun for cancer therapy.J ExpClin Cancer Res 39,184(2020).Cabezas,E.;Satterthwait,A.C.J.Am.Chem.Soc.,121,3862.(1999)

[0402] Chen et al.,Design of peptide inhibitors that bind the bZIP domain ofEpstein-Barr virus protein BZLF1.J Mol Biol 408,304-320(2011).

[0403] Cody et al.,Understanding the role of Leu22 variants in methotrexateresistance:comparison of wild-type and Leu22Arg variant mouse and humandihydrofolate reductase ternary crystal complexes with methotrexate andNADPH.Acta Crystallogr D Biol Crystallogr 61,147-155(2005).R.L.

[0404] Dai et al.,Novel DNA bis-intercalation by MLN944,a potent clinicalbisphenazine anticancer drug.J Biol Chem 279,46096-46103(2004).

[0405] Eckert et al.,AP1 transcription factors in epidermal differentiationand skin cancer.J Skin Cancer 2013,537028(2013).

[0406] Eferl et al.,AP-1:a double-edged sword in tumorigenesis.Nat RevCancer 3,859-868(2003).

[0407] Fanjul et al.,A new class of retinoids with selective inhibition ofAP-1 inhibits proliferation.Nature 372,107-111(1994).

[0408] Fairlie,D.P.,&Dantas de Araujo,A..Review stapling peptides usingcysteine crosslinking.Biopolymers,106(6),843-852.(2016)

[0409] Fujimoto,K.et al.(2008)Development of a se ries of cross-linkingagents that effectively stabilize alpha-helical structures in various shortpeptides.Chemistry 14(3):857-63.

[0410] Glover.J.N.and S.C.Harrison.Crystal structure of the heterodimericbZIP transcription factor c-Fos-c-Jun bound to DNA.Nature,1995.373(6511):p.257-61.

[0411] Haney,C.M.et al.Promoting peptide a-helix formation with dynamiccovalent oxime side-chain cross-links.Chem Commun Camb).47(39):10915-7.(2011)

[0412] Heitz et al.Twenty years of cell-penetrating peptides:from molecularmechanisms to therapeutics.Br J Pharmacol.157(2):195-206.(2009)

[0413] Holland-Nell,K.;Meldal,M.Maintaining biological activity by usingtriazoles as disulfide bond mimetics.Angew Chem Int Ed Engl.50(22):5204-6.(2011)

[0414] Jain et al.,A-ZIP53,a dominant negative reveals the molecularmechanism of heterodimerization between bZIP53,bZIP10 and bZIP25 involved inArabidopsis seed maturation.Sci Rep 7,14343(2017).

[0415] Jo,H et al.,Development ofα-helical calpain probes by mimicking anatural protein-protein interaction.Journal of the American Chemical Society,134(42),17704-17713(2012)

[0416] Jochim,A.L.,&Arora,P.S..Systematic analysis of helical proteininterfaces reveals targets for synthetic inhibitors.ACS chemical biology,5(10),919-923.(2010)

[0417] John,R.et al.,DNA binding of Jun and Fos bZip domains:homodimers andheterodimers induce a DNAconformational change in solution.Nucleic Acids Res24,4487-4494(1996).

[0418] Kaplan et al.,Increasing the affinity of selective bZIP-bindingpeptides through surface residue redesign.Protein Sci 23,940-953(2014).

[0419] Kowalczyk et al.,Peptide Lipidation-A Synthetic Strategy to AffordPeptide Based Therapeutics.Peptides and Peptide-based Biomaterials and theirBiomedical Applications.1030:185-227.(2017)

[0420] Lambert S.A.et al.,The Human Transcription Factors.Cell 175,598-599(2018).

[0421] Lathbridge et al.,Computational Competitive and Negative Design ToDerive a Specific cJun Antagonist.Biochemistry 57,6108-6118(2018).

[0422] Leduc,A.M.et al.Helix-stabilized cyclic peptides as selectiveinhibitors of steroid receptor-coactivator interactions.Proc Natl Acad Sci US A.100(20):11273-8(2003)

[0423] Lee T.I.,Young R.A.,Transcriptional regulation and its misregulationin disease.Cell 152,1237-1251(2013)

[0424] Mason et al.,Semirational design of Jun-Fos coiled coils withincreased affinity:Universal implications for leucine zipper prediction anddesign.Proc Natl Acad Sci U S A 103,8989-8994(2006).

[0425] Mason et al.,Improved stability of the Jun-Fos Activator Protein-1coiled coil motif:A stopped-flow circular dichroism kinetic analysis.J BiolChem,.282(32):p.23015-24.(2007)

[0426] Matthews et al.,Dihydrofolate reductase.The stereochemistry ofinhibitor selectivity.J Biol Chem 260,392-399(1985).

[0427] Muppidi,A.et al.Achieving cell penetration with distance-matchingcysteine cross-linkers:a facile route to cell-permeable peptide dualinhibitors of Mdm2 / Mdmx.Chem Commun(Camb).47(33):9396-8.(2011)

[0428] et al.,Elucidating the folding problem of helical peptides usingempirical parameters.Nat Struct Biol 1,399-409(1994).

[0429] Olive et al.,A dominant negative to activation protein-1(AP1)thatabolishes DNA binding and inhibits oncogenesis.J Biol Chem 272,18586-18594(1997).

[0430] Pace et al.,A helix propensity scale based on experimental studies ofpeptides and proteins.Biophys J,.75(1):p.422-7.(1998)

[0431] Perry,Samuel R et al.“Contiguous hydrophobic and charged surfacepatches in short helix-constrained peptides driva cell permeability.”Organic&biomolecular chemistry vol.16,3(2018):367-371.

[0432] Raj,M.,Bullock,B.N.,&Arora,P.S..Plucking the high hanging fruit:asystematic approach for targeting protein-protein interactions.Bioorganic&medicinal chemistry,21(14),4051-4057(2013)

[0433] Risse et al.,Asymmetrical recognition of the palindromic AP1 bindingsite(TRE)by Fos protein complexes.EMBO J 8,3825-3832(1989).

[0434] Robertson,N.S.,&Sp ring,D.R.,Using Peptidomimetics and ConstrainedPeptides as Valuable Tools for Inhibiting Protein - ProteinInteractions.Molecules(Basel,Switzerland),23(4),959.(2018)

[0435] Rodríguez-Martinez et al.,Combinatorial bZIP dimers display complexDNA-binding specificity landscapes.Elife 6,e19272(2017).

[0436] Ruan,F.et al.Metal ion-enhanced helicity in synthetic peptidescontaining unnatural,metal-ligating residues J.Am.Chem.Soc.,112(25):9403-9404(1990)

[0437] Sali,D.,M.Bycroft,and A.R.Fersht,Stabilization of protein structureby interaction of alpha-helix dipole with a charged side chain.Nature,.335(6192):p.740-3.(1988)

[0438] Seldeen et al,Evidence that the bZIP domains of the Jun transcriptionfactor bind to DNA as monomers prior to folding and homodimerization.ArchBiochem Biophys 480,75-84(2008).

[0439] Seldeen et al.,Energetic coupling along an allosteric communicationchannel drives the binding of Jun-Fos heterodimeric transcription factor toDNA.FEBS J 278,2090-2104(2011).

[0440] Szalóki et al.,Evidence for Homodime rization of the c-FosTranscription Factor in Live Cells Revealed by Fluorescence Microscopy andComputer Modeling.Mol Cell Biol 35,3785-3798(2015).

[0441] Shaulian et al.,AP-1in cell proliferation and survival.Oncogene 20,2390-2400(2001).

[0442] Shiozawa,S.and K.Tsumiyama,Pathogenesis of rheumatooid arthritis andc-Fos / AP-1.Cell Cycle,2009.8(10):p.1539-43.

[0443] Smith,Betsy A et al.“Minimally cationic cell-permeable miniatureproteins via alpha-helical arginine display.”Journal of the American ChemicalSociety vol.130,10(2008):2948-9.

[0444] Thillet et al.,Site-directed mutagenesis of mouse dihydrofolatereductase.Mutants with increased resistance to methotrexate andtrimethoprim.J Biol Chem 263,12500-12508(1988).

[0445] Timme rman et al.,Rapid and quantitative cyclization of multiplepeptide loops onto synthetic scaffolds for structural mimicry of proteinsurfaces.Chembiochem:a European journal of chemical biology,6(5),821-824.(2005)

[0446] Tsuchida et al.,Design,synthesis,and biological evaluation of newcyclic disulfide decapeptides that inhibit the binding of AP-1 to DNA.J MedChem 47,4239-4246(2004).

[0447] Tyndall,et al.,Proteases universally recognize beta strands in theiractive sites.Chem Rev,.105(3):p.973-99(2005)

[0448] Walensky,L.D.et al.Activation of apoptosis in vivo by a hyd rocarbon-stapled BH3 helix.Science.305(5689):1466-70.(2004)

[0449] Wang,D.et al.Enhanced metabolic stability and protein-bindingproperties of artificial alpha helices derived from a hydrogen-bond surrogate:application to Bcl-xL.Angew Chem Int Ed Engl.44(40):6525-9.(2005)

[0450] Wiseman,T.,et al.,Rapid measurement of binding constants and heats ofbinding using a new titration calorimeter.Anal Biochem,.179(1):p.131-7.(1989)

[0451] Worrall,J.M.Mason,Thermodynamic analysis of Jun-Fos coiled coilpeptide antagonists.FEBS J 278,663-672(2011).

[0452] Yung et a1.,Role of c-Jun N-terminal Kinase(JNK)in Obesity and Type 2Diabetes.Cells,2020.9(3).

Claims

1. A c-Jun antagonist comprising: an extended hinge region having the amino acid sequence LV[X1]EE[X2][X3]LE[X4]E (SEQ ID NO: 1); and a leucine zipper (LZ) region at the C-terminus of the extended hinge region, in: X1 is selected from V, D, K, C and R, X2 is selected from D, K, C and R, X3 is selected from V, D, C, K and R, and X4 is selected from E, D, C, K and R.

2. The c-Jun antagonist of claim 1, wherein the extended hinge region further comprises an N-terminal acidic extension having an amino acid sequence of EA[X5][X6] (SEQ ID NO: 2), in: X5 is selected from E, K and C, and X6 is selected from E and D.

3. The c-Jun antagonist of claim 2, wherein the acidic extension has the amino acid sequence EAEE (SEQ ID NO: 3).

4. The c-Jun antagonist of any one of the preceding claims, wherein X1 is V, and / or wherein X3 is V.

5. The c-Jun antagonist of any one of the preceding claims, wherein: (i) X1 is V, X2 is D, X3 is V and X4 is E; (ii) X1 is V, X2 is K, X3 is V and X4 is D; or (iii) X1 is V, X2 is C, X3 is V and X4 is C.

6. The c-Jun antagonist of any of the preceding claims, wherein the LZ region comprises: the amino acid sequence IEQLEERNYALRKEIKDLQDQ (SEQ ID NO: 7), or a variant thereof containing 1, 2, 3, 4 or 5 amino acid modifications.

7. The c-Jun antagonist of claim 6, wherein: (i) the LZ region comprises: the amino acid sequence IEQLEERNYALRKEIKDLQDQ (SEQ ID NO: 7), or a variant thereof containing 1, 2 or 3 amino acid modifications, Optionally, wherein the amino acid residues at positions corresponding to positions 16 and 20 of SEQ ID NO: 7 in the variant are K and D amino acid residues, respectively; or (ii) the LZ region comprises: the amino acid sequence IEQLEERNYALRKEICDLQCQ (SEQ ID NO: 27), or a variant thereof containing 1, 2 or 3 amino acid modifications, Optionally, the amino acid residues at positions corresponding to position 16 (position b in the heptapeptide) and position 20 (position f in the heptapeptide) of SEQ ID NO: 27 in the variant are both C amino acid residues.

8. The c-Jun antagonist according to any one of claims 1 to 5, wherein the LZ region comprises the amino acid sequence IEQLEERNYALR[X7]E[X8]K[X9]L[X 10 ]D[X 11 ](SEQ ID NO:29) or IEQLEERNYALR[X7]E[X8]C[X9]L[X10]C[X11](SEQ ID NO:30), wherein: [X7] is K, L, S, W, P, Q, R, M, T, V, A, E or G; [X8] is I, V or L; [X9] and [X10] are any amino acid residues; [X 11 ] is Q, E or K.

9. The c-Jun antagonist of claim 8, wherein the LZ region comprises an amino acid sequence selected from the group consisting of: IEQLEERNYALRSEICSLQCQ (SEQ ID NO: 66); or IEQLEERNYALRKEICELSCQ (SEQ ID NO: 67); or IEQLEERNYALRAEICNLSCQ (SEQ ID NO: 68); or IEQLEERNYALRTEICSLMCK (SEQ ID NO: 69); or IEQLEERNYALRAEICSLQCQ (SEQ ID NO: 70), Or variants thereof containing 1, 2 or 3 amino acid modifications.

10. The c-Jun antagonist of any one of the preceding claims, wherein the antagonist has the following amino acid sequence: (i) EAEELWEEDVLEEEIEQLEERNYALRKEIKDLQDQ (SEQ ID NO: 10), or a variant thereof containing 1, 2 or 3 amino acid modifications, optionally wherein in the variant the amino acid residues at positions corresponding to positions 31 and 35 of SEQ ID NO: 10 are K and D amino acid residues, respectively; (ii) EAEELVVEEKVLEDEIEQLEERNYALRKEIKDLQDQ (SEQ ID NO: 11), or a variant thereof containing 1, 2 or 3 amino acid modifications, optionally wherein the amino acid residues at positions corresponding to positions 10 and 14 of SEQ ID NO: 11 in the variant are K and D amino acid residues, respectively, and wherein the amino acid residues at positions corresponding to positions 31 and 35 of SEQ ID NO: 11 in the variant are K and D amino acid residues, respectively; (iii) EQEELVVEEDVLEEEIEQLEERNYALRKEICDLQCQ (SEQ ID NO: 28), or a variant thereof containing 1, 2 or 3 amino acid modifications, optionally wherein the amino acid residues at positions corresponding to positions 31 and 35 of SEQ ID NO: 28 in the variant are both C amino acid residues; (iv) EAEELVVEEDVLEEEIEQLEERNYALRSEICSLQCQ (SEQ ID NO: 37), or a variant thereof containing 1, 2 or 3 amino acid modifications, optionally wherein the amino acid residues at positions corresponding to positions 31 and 35 of SEQ ID NO: 28 in the variant are both C amino acid residues; or (v) EAEELVVEEDVLEEEIEQLEERNYALRAEICNLSCQ (SEQ ID NO: 39), or a variant thereof containing 1, 2 or 3 amino acid modifications, optionally wherein the amino acid residues at positions corresponding to positions 31 and 35 of SEQ ID NO: 28 in the variant are both C amino acid residues.

11. The c-Jun antagonist of any of the preceding claims, wherein the antagonist has 30 to 70 amino acids, 30 to 60 amino acids, 30 to 50 amino acids, or 30 to 40 amino acids.

12. The c-Jun antagonist of any of the preceding claims, wherein the c-Jun antagonist is capable of inhibiting the DNA binding activity of c-Jun to within 10-fold the ability of HingeW (SEQ ID NO: 48) to inhibit the DNA binding activity of c-Jun.

13. The c-Jun antagonist of any one of the preceding claims, comprising at least one amino acid residue cross-linker.

14. The c-Jun antagonist of any of the preceding claims, comprising at least one covalent i to i+4 or i to i+7 amino acid residue cross-linker.

15. The c-Jun antagonist of claim 14, comprising at least one covalent i to i+4 amino acid residue cross-linker, optionally wherein the peptide comprises two covalent i to i+4 amino acid residue cross-linkers.

16. The c-Jun antagonist of claim 14 or claim 15, wherein the covalent i to i+4 amino acid cross-linker is present at positions b to f or f to c of the heptapeptide.

17. The c-Jun antagonist of any one of claims 14 to 16, wherein the covalent i to i+4 amino acid residue cross-linker is a K to D lactam bridge, or an alkyl cross-link formed between pairs of C residues.

18. The c-Jun antagonist of any one of claims 13 to 17, wherein the alkyl cross-link formed between two C residues is formed from 1,3 dibromomethylbenzene (DBMB).

19. A nucleic acid encoding the c-Jun antagonist of any one of the preceding claims.

20. A conjugate comprising the c-Jun antagonist of any one of claims 1 to 18 conjugated to a lipid, a polymer or a second peptide, Optionally wherein the second peptide is a cell penetrating peptide.

21. A pharmaceutical composition comprising a c-Jun antagonist according to any one of claims 1 to 18, or a nucleic acid according to claim 19 or a conjugate according to claim 20, in combination with a pharmaceutically acceptable excipient or carrier.

22. The c-Jun antagonist of any one of claims 1 to 18, the nucleic acid of claim 19, the conjugate of claim 20 or the pharmaceutical composition of claim 21 for use as a medicament.

23. The c-Jun antagonist of any one of claims 1 to 18, the nucleic acid of claim 19, the conjugate of claim 20 or the pharmaceutical composition of claim 21 for use in a method of treating a disease selected from the group consisting of cancer, diabetes, cardiovascular disease, autoimmune disease, arthritis and neurodegenerative disease.

24. A method of inhibiting c-Jun, comprising administering a peptide according to any one of claims 1 to 18, a nucleic acid according to claim 19 or a conjugate according to claim 20 to a cell comprising or expressing c-Jun in vitro.

25. The c-Jun antagonist of any one of claims 1 to 18, Use of the nucleic acid according to claim 19, the conjugate according to claim 20 or the pharmaceutical composition according to claim 21 for the preparation of a medicament for treating a disease selected from the group consisting of cancer, diabetes, cardiovascular disease, autoimmune disease, arthritis and neurodegenerative disease.